

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 1 380 595 A1**

(12)

**EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

(43) Date of publication:  
14.01.2004 Bulletin 2004/03(51) Int Cl.7: **C08B 37/00**(21) Application number: **02705093.9**(86) International application number:  
**PCT/JP2002/002213**(22) Date of filing: **08.03.2002**(87) International publication number:  
**WO 2002/072594 (19.09.2002 Gazette 2002/38)**(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR**(30) Priority: **09.03.2001 JP 2001067282**(71) Applicant: **Kabushiki Kaisha Hayashibara  
Seibutsu Kagaku Kenkyujo  
Okayama-shi, Okayama 700-0907 (JP)**(72) Inventors:  
• **AGA, Hajime, c/o Kabushiki Kaisha Hayashibara  
Okayama-shi, Okayama 700-0907 (JP)**  
• **HIGASHIYAMA, Takanobu, c/o K.K. Hayashibara  
Okayama-shi, Okayama 700-0907 (JP)**

- **WATANABE, Hikaru,  
c/o Kabushiki Kaisha Hayashibara  
Okayama-shi, Okayama 700-0907 (JP)**
- **SONODA, Tomohiko,  
c/o Kabushiki Kaisha Hayashibara  
Okayama-shi, Okayama 700-0907 (JP)**
- **KUBOTA, Michio,  
c/o Kabushiki Kaisha Hayashibara  
Okayama-shi, Okayama 700-0907 (JP)**

(74) Representative: **Daniels, Jeffrey Nicholas et al  
Page White & Farrer  
54 Doughty Street  
London WC1N 2LS (GB)**(54) **BRANCHED CYCLIC TETRASSACHARIDE, PROCESS FOR PRODUCING THE SAME, AND  
USE**

(57) The object of the present invention is to provide a novel glycosyl derivative of cyclotetrasaccharide represented by cyclo{→ 6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→)} and it is solved by providing a branched cyclotetrasaccharide, wherein one or more hydrogen atoms in the hydroxyl groups of cyclotetrasaccharide are replaced with an optionally

substituted glycosyl group, with the proviso that, when only one hydrogen atom in the C-6 hydroxyl group among the above hydrogen atoms is substituted with an optionally-substituted glycosyl group, the substituted glycosyl group is one selected from those excluding D-glucosyl group.

## Description

## Technical Field


**[0001]** The present invention relates to a novel branched cyclic tetrasaccharide, more particularly, a glycosyl derivative of a cyclic tetrasaccharide represented by the chemical formula of  $\text{cyclo}\{\rightarrow 6\}\text{-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 3\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 6\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 3\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow\}$ , a process for producing the same, and uses thereof.

## Background Art


**[0002]**  $\alpha$ -,  $\beta$ -, and  $\gamma$ -Cyclodextrins, which consist of 6, 7, and 8 glucose molecules that are linked each other via the  $\alpha$ -1,4 glucosyl linkage, respectively, have been known as cyclic saccharides composed of glucose units. These cyclodextrins have been used in a variety of fields due to their advantageous inherent properties of non-reducibility, tasteless, enclosing hydrophobic materials, etc. There have been being pursued remarkable researches directed to improve properties of cyclodextrins and impart additional new functions thereupon. For example, Japanese Patent Kokai Nos. 9,708/94, 14,789/94, 16,705/94, 298,806/94, and 25,305/98 proposed branched cyclodextrins with different branching structures, which are prepared by coupling a glycosyl group such as a glucosyl, galactosyl, mannosyl, glucosaminyl, or N-acetylglucosaminyl group to cyclodextrins; processes for producing the same; and uses thereof.

**[0003]** As an example of cyclic saccharide reported recently, there is a cyclic tetrasaccharide, reported by Gregory L. Cote et al. in *European Journal of Biochemistry*, Vol. 226, pp. 641-648 (1994), composed of glucose molecules linked each other via the alternating  $\alpha$ -1,3 and  $\alpha$ -1,6 bonds and having the structures represented by Chemical Formulae A and B as bonding fashions between atoms and between glucosyl groups, respectively. In addition to Chemical Formulae A and B,  $\text{cyclo}\{\rightarrow 6\}\text{-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 3\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 6\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 3\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow\}$  belongs to the above cyclic tetrasaccharide. Throughout the specification, the term "cyclotetrasaccharide" means the above-identified cyclic tetrasaccharide.

## Chemical Formula A:



## Chemical Formula B:




**[0004]** The above report by Cote et al. shows that cyclotetrasaccharide is formed by allowing alternan, a type of polysaccharide composed of glucose molecules linked via the alternating  $\alpha$ -1,3 and  $\alpha$ -1,6 bonds to act on alternanase, a type of hydrolyzing enzyme. Thereafter, cyclotetrasaccharide has been expected to be used in different fields similarly as in or much more useful than conventional cyclodextrins. The method of the report, however, may not suitable for

an industrial-scale production of cyclotetrasaccharide, because alternan used as a starting material is not easily obtainable and the yield of cyclotetrasaccharide from the material is insufficient in view of industrial-scale production.


[0005] The same applicant as the present invention disclosed an  $\alpha$ -isomaltosyl-transferring enzyme, a novel enzyme which forms cyclotetrasaccharide when acts on a saccharide having a glucose polymerization degree of at least three and having both an isomaltosyl group at the non-reducing end and the  $\alpha$ -1,4 glucosyl bond as a linkage other than the linkage at the non-reducing end (abbreviated as " $\alpha$ -isomaltosylglucosaccharide" hereinafter) as disclosed in Japanese Patent Application No. 149,484/2000, and Japanese Patent Application No 229,557/2000 (International Publication No. WO 01/90,338 A1) applied for based on the above Japanese Patent Application; and also disclosed an  $\alpha$ -isomaltosylglucosaccharide-forming enzyme, a novel enzyme which forms  $\alpha$ -isomaltosylglucosaccharide when acts on a maltooligosaccharide having a glucose polymerization degree of at least three, as disclosed in Japanese Patent Application No. 233,364/2000 and Japanese Patent Application No. 234,937/2000 (International Publication No. WO 02/10,361 A1), applied for based on Japanese Patent Application No. 233,364/2000. Further, the above applicant proposed a method to produce cyclotetrasaccharide as a main product from starch, a widely, commonly used material for producing foods by using the  $\alpha$ -isomaltosylglucosaccharide-forming enzyme and the  $\alpha$ -isomaltosyl-transferring enzyme in combination, as disclosed in Japanese Patent Application Nos. 233,364/2000 and 234,937/2000 (International Publication No. WO 02/10,361 A1). This proposal was a breakthrough for an industrial scale production of cyclotetrasaccharide.

[0006] Thus, the study on cyclotetrasaccharide has just merely been started, and further studies for elucidating unknown functions and developing new uses of cyclotetrasaccharide are now being greatly expected. Even though cyclotetrasaccharide is a known compound, there is found no study to produce derivatives thereof as a main object, because cyclotetrasaccharide has not yet been easily obtained. So far found is merely the above report by Cote et al. that reported only a 6-O-glucopyranosyl derivative of cyclotetrasaccharide, represented by Chemical Formula C, isolated and identified as a by-product in a negligible yield through the action of alternanase on alternan. Chemical Formula D represents the 6-O-glucopyranosyl derivative in terms of bonding fashions between glucosyl groups.

Chemical Formula C:



Chemical Formula D:



[0007] Similarly as in cyclodextrins, supplying of glycosyl derivatives of cyclotetrasaccharide would provide a useful knowledge for developing uses of cyclotetrasaccharide through analyses on their properties, and also it remarkably influences on the development of uses of novel saccharides, obtained by improving or modifying the properties and functions of cyclotetrasaccharide.


#### Disclosure of Invention

[0008] In view of the above backgrounds, the first object of the present invention is to provide a novel glycosyl derivative of cyclotetrasaccharide, the second object is to provide a process for producing the same, and the third object is to provide uses thereof.

[0009] To solve the above objects, the present inventors firstly found that cyclotetrasaccharide-related-saccharides were formed as by-products in the reaction system accomplished by the present inventors, where cyclotetrasaccharide was formed by subjecting a partial starch hydrolyzate to the action of  $\alpha$ -isomaltosyl-transferring enzyme and  $\alpha$ -isomaltosylglucosaccharide-forming enzyme, and then tried to isolate and identify the by-products. As a result, they confirmed that all the by-products were novel glycosyl derivatives of cyclotetrasaccharide. Further, they reacted cyclotetrasaccharide, prepared by the above two-types of enzymes, with these enzymes together with well known saccharide-related-enzymes in the presence of different glycosyl donors. As a result, they found that various glycosyl derivatives were obtained through the action of the above enzymes, cyclomaltodextrin glucanotransferase,  $\beta$ -galactosidase,  $\alpha$ -galactosidase, lysozyme, and other saccharide-related-enzymes such as glycosyltransferase, glycosylhydrolase, and glycosylphosphatase. They isolated the formed glycosyl derivatives of cyclotetrasaccharide and examined their properties, and confirmed that the glycosyl derivatives can be advantageously used in the fields of food products, cosmetics, pharmaceuticals, etc. The present invention was made based on the above self-findings by the present inventors.

[0010] The present invention solves the first object by providing branched cyclotetrasaccharides, i.e., glycosyl derivatives of cyclotetrasaccharide represented by Formula 1.

Formula 1:



wherein in Formula 1,  $R_1$  to  $R_{12}$  each independently represents an optionally substituted glycosyl group or hydrogen atom, with the proviso that all of  $R_1$  to  $R_{12}$  are not hydrogen atom at the same time and that, when either  $R_4$  or  $R_{10}$  is an optionally substituted glycosyl group, the glycosyl group  $R_4$  or  $R_{10}$  is a glycosyl group other than D-glucopyranosyl group.

[0011] The present invention solves the second object by providing a process for producing the branched cyclotetrasaccharides of the present invention, which uses an enzyme capable of transferring a glycosyl group from a monosaccharide, oligosaccharide, or polysaccharide to cyclotetrasaccharide; and comprises a step of forming the branched cyclotetrasaccharides by reacting the above enzyme with a mixture of cyclotetrasaccharide and the above monosaccharide, oligosaccharide, or polysaccharide, and collecting the formed branched cyclotetrasaccharides.

[0012] Further, the present invention solves the third object by providing a composition in the form of a food product, cosmetic, or pharmaceutical, which comprises the branched cyclotetrasaccharide(s) of the present invention.



Brief Description of Drawings**[0013]**

- 5 FIG.1 is a chromatogram of cyclotetrasaccharide on high-performance liquid chromatography (abbreviated as "HPLC" hereinafter).  
 FIG.2 is a  $^1\text{H}$ -NMR spectrum of cyclotetrasaccharide.  
 FIG.3 is a  $^{13}\text{C}$ -NMR spectrum of cyclotetrasaccharide.  
 FIG.4 is a  $^{13}\text{C}$ -NMR spectrum of the branched cyclotetrasaccharide of the present invention, represented by Chem-  
 10 ical Formula 1.  
 FIG.5 is a  $^{13}\text{C}$ -NMR spectrum of the branched cyclotetrasaccharide of the present invention, represented by Chem-  
 ical Formula 3.  
 FIG.6 is a  $^{13}\text{C}$ -NMR spectrum of the branched cyclotetrasaccharide of the present invention, represented by Chem-  
 ical Formula 4.  
 15 FIG.7 is a  $^{13}\text{C}$ -NMR spectrum of the branched cyclotetrasaccharide of the present invention, represented by Chem-  
 ical Formula 5.  
 FIGs . 8a and 8b are respectively a chromatogram (a) on HPLC for a reaction mixture obtained by reacting CGTase  
 with a mixture of cyclotetrasaccharide and  $\alpha$  -cyclodextrin, and a chromatogram (b) on HPLC for a reaction mixture  
 obtained by contacting glucoamylase with the above mixture after reacted with CGTase.  
 20 FIG.9 is a  $^{13}\text{C}$ -NMR spectrum of the branched cyclotetrasaccharide of the present invention, represented by Chem-  
 ical Formula 2.  
 FIG.10 is a  $^{13}\text{C}$ -NMR spectrum of the branched cyclotetrasaccharide of the present invention, represented by  
 Chemical Formula 6.  
 FIG.11 is a  $^{13}\text{C}$ -NMR spectrum of the branched cyclotetrasaccharide of the present invention, represented by  
 25 Chemical Formula 8.  
 FIG.12 is a  $^{13}\text{C}$ -NMR spectrum of the branched cyclotetrasaccharide of the present invention, represented by  
 Chemical Formula 7.  
 FIG.13 is a  $^{13}\text{C}$ -NMR spectrum of the branched cyclotetrasaccharide of the present invention, represented by  
 Chemical Formula 9.  
 30 FIG.14 is a  $^{13}\text{C}$  -NMR spectrum of the branched cyclotetrasaccharide of the present invention, represented by  
 Chemical Formula 10.  
 FIG.15 is an X-ray diffraction spectrum for a crystal of the branched cyclotetrasaccharide of the present invention,  
 represented by Chemical Formula 1.  
 FIG.16 is an X-ray diffraction spectrum for a crystal of the branched cyclotetrasaccharide of the present invention,  
 35 represented by Chemical Formula 2.  
 FIG.17 is an X-ray diffraction spectrum for a crystal of the branched cyclotetrasaccharide of the present invention,  
 represented by Chemical Formula 3.  
 FIG.18 is an X-ray diffraction spectrum for a crystal of the branched cyclotetrasaccharide of the present invention,  
 represented by Chemical Formula 6.  
 40 FIG.19 is an X-ray diffraction spectrum for a crystal of the branched cyclotetrasaccharide of the present invention,  
 represented by Chemical Formula 7.  
 FIG.20 shows a thermal property of the branched cyclotetrasaccharide of the present invention, represented by  
 Chemical Formula 1 on thermogravimetric analysis.  
 FIG.21 shows a thermal property of the branched cyclotetrasaccharide of the present invention, represented by  
 45 Chemical Formula 2 on thermogravimetric analysis.  
 FIG.22 shows a thermal property of the branched cyclotetrasaccharide of the present invention, represented by  
 Chemical Formula 3 on thermogravimetric analysis.  
 FIG.23 shows a thermal property of the branched cyclotetrasaccharide of the present invention, represented by  
 Chemical Formula 6 on thermogravimetric analysis.  
 50 FIG.24 shows a thermal property of the branched cyclotetrasaccharide of the present invention, represented by  
 Chemical Formula 7 on thermogravimetric analysis.


Best Mode for Carrying Out the Invention

- 55 **[0014]** Preferred embodiments of the present invention are described below in more detail:

## 1. Branched cyclotetrasaccharides

**[0015]** Novel branched cyclotetrasaccharides, which the present invention provides, have the structure represented by Formula 1.

Formula 1:



wherein in Formula 1,  $R_1$  to  $R_{12}$  each independently represents an optionally substituted glycosyl group or hydrogen atom, with the proviso that all of  $R_1$  to  $R_{12}$  are not hydrogen atom at the same time and that when either  $R_4$  or  $R_{10}$  is an optionally substituted glycosyl group, the glycosyl group  $R_4$  or  $R_{10}$  is a glycosyl group other than D-glucopyranosyl group. The term "glycosyl group" as referred to as in the present invention means an atomic group represented by a structure where an anomeric hydroxyl group is removed from the molecular structure of a saccharide. The term "saccharides" as referred to as in the present invention means a general term for compounds including polyalcohols and their aldehydes, ketons and acids; amino sugars and their derivatives; and oligosaccharides, polysaccharides, and their condensed compounds. The term "substituents in glycosyl groups with an optional group" as referred to as in the present invention means substituent groups which can substitute hydrogen(s) of one or more non-anomeric hydroxyl groups in a saccharide molecule, or of one or more non-anomeric hydroxyl groups and amino groups when the saccharide molecule is an amino sugar. Examples of such substituent groups are alkyl, acyl, acetyl, phosphoric acid, and sulfuric acid groups.

**[0016]** Examples of the glycosyl groups that are positioned at the branched parts of the branched cyclotetrasaccharides of the present invention, i.e., one or more glycosyl groups selected from  $R_1$  to  $R_{12}$  in Formula 1 are optionally substituted  $\{\alpha\text{-D-glucopyranosyl-(1}\rightarrow\text{4)}\}_n$   $\alpha\text{-D-glucopyranosyl}$  groups, with the proviso that "n" represents an integer of 0 or over and, when at least two of  $R_1$  to  $R_{12}$  are the above glycosyl groups, the integers of "n" in each glycosyl groups are independent each other; optionally substituted  $\alpha\text{-D-glucopyranosyl-(1}\rightarrow\text{6)}\text{-}\{\alpha\text{-D-glucopyranosyl-(1}\rightarrow\text{3)}\text{-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow\text{6)}\}_n$   $\alpha\text{-D-glucopyranosyl}$  group, with the proviso that "n" represents an integer of 0 or over and, when at least two of  $R_1$  to  $R_{12}$  are the above glycosyl groups, the integers of "n" in each glycosyl groups are independent each other; optionally substituted  $\{\beta\text{-D-galactopyranosyl-(1}\rightarrow\text{6)}\}_n$   $\beta\text{-D-galactopyranosyl}$  groups, with the proviso that "n" represents an integer of 0 or over and, when at least two of  $R_1$  to  $R_{12}$  are glycosyl groups, the integers of "n" in each glycosyl groups are independent each other; optionally substituted  $\alpha\text{-D-galactopyranosyl}$  groups; and optionally substituted  $\beta\text{-D-chitosaminyl}$  groups. The branched cyclotetrasaccharides of the present invention may have one or more of the above-mentioned groups intramolecularly.

**[0017]** The first more concrete example of the branched cyclotetrasaccharides are those wherein  $R_1$  and/or  $R_7$  in Formula 1 are optionally substituted  $\{\alpha\text{-D-glucopyranosyl-(1}\rightarrow\text{4)}\}_n$   $\alpha\text{-D-glucopyranosyl}$  groups, with the proviso that "n" represents an integer of 0 or over and, when both  $R_1$  and  $R_7$  are such glycosyl groups, the integers of "n" in each groups are independent each other. Examples of the structural formulae thereof are Chemical Formulae 1 and 2 as shown in Experiments 3-4 and 4-3.

**[0018]** The second more concrete example of the branched cyclotetrasaccharides are those wherein  $R_2$  and/or  $R_8$  in Formula 1 are optionally substituted  $\alpha\text{-D-glucopyranosyl-(1}\rightarrow\text{6)}\text{-}\{\alpha\text{-D-glucopyranosyl-(1}\rightarrow\text{3)}\text{-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow\text{6)}\}_n$   $\alpha\text{-D-glucopyranosyl}$  groups, with the proviso that "n" represents an integer of 0 or over and, when both

$R_2$  and  $R_8$  are such glycosyl groups, the integers of "n" in each group are independent each other. Examples of the structural formulae thereof are Chemical Formulae 3 and 4 as shown in Experiment 3-4.

[0019] The third more concrete example of the branched cyclotetrasaccharides are those wherein  $R_2$  and/or  $R_8$  in Formula 1 are optionally substituted  $\{\beta\text{-D-galactopyranosyl-(1}\rightarrow\text{6)}\}_n$   $\beta\text{-D-galactopyranosyl}$  groups, with the proviso that "n" represents an integer of 0 or over and, when both  $R_2$  and  $R_8$  are such glycosyl groups, the integers of "n" in each group are independent each other. Example of the structural formula thereof is Chemical Formula 6 as shown in Experiment 4-4.

[0020] The forth more concrete example of the branched cyclotetrasaccharides are those wherein  $R_4$  and/or  $R_{10}$  in Formula 1 are optionally substituted  $\{\beta\text{-D-galactopyranosyl-(1}\rightarrow\text{6)}\}_n$   $\beta\text{-D-galactopyranosyl}$  groups, with the proviso that "n" represents an integer of 0 or over and, when both  $R_4$  and  $R_{10}$  are such glycosyl groups, the integers of "n" in each group are independent each other. Examples of the structural formulae thereof are Chemical Formulae 7 and 8 as shown in Experiment 4-5.

[0021] The fifth more concrete example of the branched cyclotetrasaccharides are those wherein  $R_4$  and/or  $R_{10}$  in Formula 1 are optionally substituted  $\alpha\text{-D-galactopyranosyl}$  groups. Example of the structural formula thereof is Chemical Formula 9 as shown in Experiment 4-6.

[0022] The sixth more concrete example of the branched cyclotetrasaccharides are those wherein  $R_2$  and/or  $R_8$  in Formula 1 are optionally substituted  $\beta\text{-D-chitosaminyl}$  groups ("a chitosaminyl group" is also generally called "a glucosaminyl group"). Example of the structural formula thereof is Chemical Formula 10 as shown in Experiment 4-7.

[0023] Though the above examples of the branched cyclotetrasaccharides of the present invention are respectively classified and exemplified based on their constituent saccharides positioned at their branched parts, the branched cyclotetrasaccharides may be those which have either one of these branched parts or two or more of them in an appropriate combination. For example, a branched cyclotetrasaccharide which combinationally has both the structure of the branched part represented by the above first example, and the structure of the branched part represented by any of the above second to sixth examples. An example of such structures is Chemical Formula 5 in Experiment 3-4.

[0024] As long as the branched cyclotetrasaccharides of the present invention have any of the above-mentioned structures, they should not be restricted to those which are produced by specific methods such as organic syntheses and include those which are produced by enzymatic reactions. However, since the branched cyclotetrasaccharides are efficiently produced by the process according to the present invention described in detail below, those which are produced by the above process are advantageously used in a variety of fields. The branched cyclotetrasaccharides of the present invention are provided in the form of a product consisting essentially of the branched cyclotetrasaccharides as a saccharide component, usually, in a purified form with a purity of at least 90%, preferably, at least 95%, and more preferably, at least 97%; in the form of a solution, amorphous powder, or molasses; or in the form of an isolated crystal. The branched cyclotetrasaccharides in a crystal form can be isolated by crystallizing in water, an organic solvent such as lower alcohols and dimethylformamide, or a solvent in a mixture form of two or more of the above solvents selected appropriately; and further separating the resulting crystals in a conventional manner. Crystals of branched cyclotetrasaccharides in a hydrous or anhydrous form can be obtained by crystallization in water. Examples of such hydrous crystal are those of the branched cyclotetrasaccharides represented by Chemical Formulae 1, 2, 3, 6 and 7. These hydrous crystals can be converted into anhydrous ones by heating at normal pressure or reduced pressure and at ambient temperature. Crystals of these branched cyclotetrasaccharides can be identified by conventional X-ray powder diffraction analysis. For example, upon the analysis, the branched cyclotetrasaccharides represented by Chemical Formulae 1, 2, 3, 6, and 7 have main diffraction angles (2 $\theta$ ) of (1) 8.1°, 12.2°, 14.2°, and 15.4°; (2) 5.6°, 8.8°, 16.9°, and 21.9°; (3) 7.9°, 12.1°, 17.9°, and 20.2°; (4) 11.0°, 12.3°, 12.8°, and 24.9°; and (5) 8.7°, 13.0°, 21.7°, and 26.1°, respectively. Each branched cyclotetrasaccharide can be provided in the form of a saccharide composition comprising the same as a main ingredient. The saccharide composition, which contains one or more of the branched cyclotetrasaccharides in an amount, usually, of at least 50%, preferably, at least 60%, more preferably, at least 70%, and more preferably, at least 80% against the total amount of sugar components, on a dry solid basis (d.s.b.), is provided in the form of a solution, syrup, block, granule, crystalline powder containing hydrous and/or anhydrous crystal, amorphous crystalline powder, or molasses of the branched cyclotetrasaccharide(s).

## 2. Process for producing branched cyclotetrasaccharides

[0025] The process for producing the branched cyclotetrasaccharides of the present invention employs the action of an enzyme that transfers a glycosyl group from a monosaccharide, oligosaccharide, or polysaccharide to cyclotetrasaccharide, and it is characterized in that it comprises the steps of allowing the enzyme to act on a mixture of cyclotetrasaccharide and any of the above monosaccharide, oligosaccharide, and polysaccharide to form the desired branched cyclotetrasaccharides, and collecting the produced branched cyclotetrasaccharides.

## 2.1. Preparation of cyclotetrasaccharides

[0026] The process for producing cyclotetrasaccharide is not specifically restricted. Examples of such are (1) a process for producing cyclotetrasaccharide by contacting alternanase, i.e., a hydrolyzing enzyme, with alternan, i.e., a polysaccharide reported by Gregory L. Cote et al. in *European Journal of Biochemistry*, Vol. 226, pp. 641-648 (1994); (2) a process for producing cyclotetrasaccharide by contacting  $\alpha$ -isomaltosyl-transferring enzyme with  $\alpha$ -isomaltosylglucosaccharide; and (3) a process for producing cyclotetrasaccharide by contacting both  $\alpha$ -isomaltosylglucosaccharide-forming enzyme and  $\alpha$ -isomaltosyl-transferring enzyme with a saccharide, having a glucose polymerization degree of at least two and the  $\alpha$ -1,4 glucosyl bond as a linkage at its reducing end, such as a starch hydrolyzate. The terms " $\alpha$ -isomaltosylglucosaccharide-forming enzyme" and " $\alpha$ -isomaltosyl-transferring enzyme" as referred to as in the present invention mean enzymes having the following enzymatic activities (A) and (B), respectively, independently of their other enzymatic activities, not specified in (A) and (B), such as physicochemical properties and origins.

(A) Acting on a saccharide, which has a glucose polymerization degree of "n" ("n" represents an integer of at least two) and the  $\alpha$ -1,4 glucosyl bond as a linkage at its non-reducing end, to form a saccharide having a glucose polymerization degree of "n+1" and having both the  $\alpha$ -1,6 glucosyl bond as a linkage at its non-reducing end and the  $\alpha$ -1,4 glucosyl bond as a linkage other than the above linkage at its non-reducing end, without substantially increasing the reducing power of the saccharide.

(B) Acting on a saccharide, which has a glucose polymerization degree of at least three, the  $\alpha$ -1,6 glucosyl bond as a linkage at its non-reducing end, and the  $\alpha$ -1,4 glucosyl bond as a linkage other than the above linkage at its non-reducing end, to form cyclotetrasaccharide represented by  $\text{cyclo}\{\rightarrow 6\}\text{-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 3\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 6\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 3\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow\}$ .

[0027] The formation mechanism of cyclotetrasaccharide by the above process (3) is roughly estimated as follows:

(I)  $\alpha$ -Isomaltosylglucosaccharide-forming enzyme acts on a glucose residue positioning at the reducing end of an  $\alpha$ -1,4 glucan chain such as in glycogen or starch hydrolyzates, and intermolecularly transfers the glucose residue to the C-6 hydroxyl group of a glucose group positioning at the non-reducing end of another intact  $\alpha$ -1,4 glucan chain, and to form an  $\alpha$ -1,4 glucan chain having an  $\alpha$ -isomaltosyl group at its non-reducing end.

(II)  $\alpha$ -Isomaltosyl-transferring enzyme acts on the resulting  $\alpha$ -1,4 glucan chain, having an isomaltosyl group at its non-reducing end, and intermolecularly transfers the isomaltosyl group to the C-3 hydroxyl group of a glucose group positioning at the non-reducing end of another intact  $\alpha$ -1,4 glucan chain having an isomaltosyl group at its non-reducing end to form an  $\alpha$ -1,4 glucan chain having an isomaltosyl-1,3-isomaltosyl group at its non-reducing end.

(III) Subsequently,  $\alpha$ -isomaltosyl-transferring enzyme acts on the resulting  $\alpha$ -1,4 glucan chain, having an isomaltosyl-1,3-isomaltosyl group at its non-reducing end, to release the isomaltosyl-1,3-isomaltosyl group from the  $\alpha$ -1,4 glucan chain via the intramolecular transferring action and to circularize the released group for forming cyclotetrasaccharide.

(IV) The resulting  $\alpha$ -1,4 glucan chain is sequentially received the above enzymatic reactions (I) to (III) to increase the yield of cyclotetrasaccharides.

[0028] To produce cyclotetrasaccharide on an industrial scale, among the above processes, the processes (2) and (3) are relatively advantageous in terms of its production cost and labors, particularly, the process (3) is more preferable. With reference to the above process (3) mainly, the process for producing cyclotetrasaccharide is explained below:

### 2.1.1. $\alpha$ -Isomaltosyl-transferring enzyme and $\alpha$ -isomaltosylglucosaccharide-forming enzyme

[0029]  $\alpha$ -Isomaltosyl-transferring enzyme and  $\alpha$ -isomaltosylglucosaccharide-forming enzyme can be obtained, for example, by culturing a microorganism which produces either or both of the enzymes, and applying conventional methods for preparing enzymes to the resulting culture. *Bacillus globisporus* C9 strain was deposited on April 25, 2000, with International Patent Organism Depositary National Institute of Advanced Industrial Science and Technology Tsukuba Central 6, 1-1, Higashi 1-Chome Tsukuba-shi, Ibaraki-ken, Japan, and has been maintained therein under the accession number of FERM BP-7143; and *Bacillus globisporus* C11 strain was deposited on April 25, 2000, with the same depositary as above and has been maintained therein under the accession number of FERM BP-7144, are particularly useful as sources of the above enzymes because they produce both the enzymes (the above microorganisms may be called "Strain C9" and "Strain C11", hereinafter).

[0030] The nutrient culture media and culture conditions used for culturing Strain C9, FERM BP-7143, and Strain C11, FERM BP-7144, are as follows: Examples of the carbon sources usable in the present invention are starches

and phytoglycogens from plants; glycogens and pullulans from animals and microorganisms; partial hydrolyzates thereof; saccharides such as D-glucose, D-fructose, lactose, sucrose, mannitol, L-sorbitol, and molasses; and organic acids such as citric acid and succinic acid. The concentration of these carbon sources in nutrient culture media is appropriately changed depending on their types. The nitrogen sources usable in the present invention are, for example, inorganic

nitrogen-containing compounds such as ammonium salts and nitrates; and organic nitrogen-containing compounds such as urea, corn steep liquor, casein, yeast extract, and beef extract. The inorganic ingredients usable in the present invention are, for example, salts of calcium, magnesium, potassium, sodium, phosphoric acid, manganese, zinc, iron, copper, molybdenum, and cobalt. If necessary, amino acids and vitamins can be appropriately used in combination.

**[0031]** Explaining the culture conditions, microorganisms are preferably cultured, usually, under aerobic conditions at temperatures, usually, of 4 to 40°C, preferably, 20 to 37°C, at pHs, usually, of 4 to 10, preferably, 5 to 9, for 10 to 150 hours. The concentration of dissolved oxygen (DO) can be controlled during the culturing, and it can be kept within the range of 0.5-20 ppm, for example, by means of controlling the aeration rate and the stirring speed, increasing or decreasing the oxygen concentration in gas used for aeration, and increasing or decreasing the inner pressure of fermenters. The cultivation is freely carried out batchwise, in a continuous manner, or in a semi-continuous manner, as long as it affords the conditions in which microorganisms can grow and produce  $\alpha$ -isomaltosyl-transferring enzyme.

**[0032]** The cultures of Strain C9, FERM BP-7143, and Strain C11, FERM BP-7144, usually contain  $\alpha$ -isomaltosyl-transferring enzyme and  $\alpha$ -isomaltosylglucosaccharide-forming enzyme. Therefore, in the process for producing cyclotetrasaccharide, the above cultures can be used intact as an enzyme agent or used after purified into an enzyme agent which contains either or both of the above enzymes. For example, a partially purified enzyme agent, containing both the enzymes, can be obtained by removing cells from the cultures by means of a conventional liquid-solid separation method, collecting the resulting supernatant, and optionally subjecting the supernatant to conventional methods for concentrating proteins such as salting out using ammonium sulfate, sedimentation using acetone or alcohol, concentration *in vacuo*, and concentration using membranes. If necessary, the enzyme agent thus obtained can be further treated by appropriately combining with conventional methods for purifying enzymes such as gel-filtration chromatography, ion-exchange chromatography, affinity chromatography, and hydrophobic chromatography. From the separated fractions, those with the desired enzymatic activities are separately collected into enzyme agents having either of the enzymes purified to the desired level.

**[0033]** The enzymatic activity of  $\alpha$ -isomaltosyl-transferring enzyme can be assayed as follows: Dissolve panose in 100 mM acetate buffer (pH 6.0) to give a concentration of 2% (w/v) for a substrate solution, add 0.5 ml of an enzyme solution to 0.5 ml of the substrate solution, and keep the mixture at 35°C for 30 min to proceed the formation of cyclotetrasaccharide from panose. In the reaction system, glucose is formed together with cyclotetrasaccharide from panose. After the reaction, boil the reaction mixture for 10 min to suspend the reaction. Subject the resulting reaction mixture to the glucose oxidase method to quantify the glucose formed in the reaction mixture. In the present invention, one unit activity of  $\alpha$ -isomaltosyl-transferring enzyme is defined as the enzyme amount that forms one micromole of glucose per minute under the above enzymatic reaction conditions.

**[0034]** The  $\alpha$ -isomaltosylglucosaccharide-forming enzyme activity can be assayed as follows: Add 0.5 ml of an enzymatic solution to 0.5 ml of a substrate solution obtained by dissolving maltotriose in 100 mM acetate buffer (pH 6.0) to give a concentration of 2% (w/v) is added, incubate the mixture at 35°C for 60 min to proceed the formation reaction of isomaltosylmaltose from maltotriose. In the reaction system, maltose is formed together with isomaltosylmaltose from maltotriose. Thereafter, boil the reaction mixture for 10 min to suspend the enzymatic reaction. Subject the resulting mixture to conventional HPLC for detecting and quantifying maltose formed in the reaction mixture to quantify the maltose. In the present invention, one unit activity of the  $\alpha$ -isomaltosylglucosaccharide-forming enzyme is defined as the enzyme amount that forms one micromole of maltose per minute under the above enzymatic reaction conditions.

**[0035]** Table 1 shows the physicochemical properties of both the enzymes obtained from Strain C9, FERM BP-7143; and Strain C11, FERM BP-7144, which are confirmed by the index in the above defined enzymatic activities.

Table 1

	$\alpha$ -Isomaltosyl-transferring enzyme	$\alpha$ -Isomaltosylglucosaccharide- forming enzyme
Molecular weight (Analysis method)	About 82,000 to about 132,000 daltons (SDS-PAGE)	About 117,000 to about 160,000 daltons (SDS-PAGE)
Isoelectric point (Analysis method)	pI of about 5.0 to about 6.0 (Isoelectrophoresis using ampholine)	pI of about 4.7 to about 5.7 (Isoelectrophoresis using mpholine)
Optimum temperature (Analysis condition)	About 45°C to about 50°C (Reaction at pH 6.0 for 30 min)	About 40°C to about 45°C (Reaction at pH 6.0 for 60 min) About 45°C to about 50°C (Reaction under the same condition as above in the presence of 1 mM $\text{Ca}^{2+}$ )

(Continued)

$\alpha$ -Isomaltosyl-transferring enzyme	$\alpha$ -Isomaltosylglucosaccharide- forming enzyme
Optimum pH	pH of about 6.0 to about 6.5
(Analysis condition)	(Reaction at 35°C for 60 min)
Thermal stability	About 35°C to about 40 °C or lower
(Analysis condition)	(Reaction at pH 6.0 for 60 min)
	About 40°C to about 45°C or lower
	(Reaction under the same condition
	as above in the presence of 1 mM Ca <sup>2+</sup> )
pH Stability	pH of about 4.5 to about 10.0
(Analysis condition)	(Incubated at 4°C for 24 hours)

[0036] When an enzyme agent is a composition of  $\alpha$ -isomaltosyl-transferring enzyme and  $\alpha$ -isomaltosylglucosaccharide-forming enzyme, it has an activity of forming cyclotetrasaccharide from partial starch hydrolyzates. The activity of forming cyclotetrasaccharide from partial starch hydrolyzates (the term "a cyclotetrasaccharide forming activity" means the above activity, hereinafter) can be assayed as follows: Add 0.5 ml of an enzyme solution to 0.5 ml of a substrate solution obtained by dissolving "PINE-DEX #100™", a partial starch hydrolyzate commercialized by Matsutani Chemical Ind., Tokyo, Japan, in 50 mM acetate buffer (pH 6.0) to give a concentration of 2% (w/v), incubate the mixture at 35°C for 60 min to proceed the formation reaction of cyclotetrasaccharide. Thereafter, boil the reaction mixture for 10 min to suspend the enzymatic reaction, and add to the resulting mixture one milliliter of 50 mM acetate buffer (pH 5.0) with 70 units/ml of "TRANSGLUCOSIDASE L AMANO™", an  $\alpha$ -glucosidase commercialized by Amano Pharmaceutical Co., Ltd., Aichi, Japan, and 27 units/ml of a glucoamylase commercialized by Nagase Biochemicals, Ltd., Kyoto, Japan; incubate the mixture at 50°C for 60 min, and boil the mixture for 10 min to suspend the actions of  $\alpha$ -glucosidase and glucoamylase. Then, subject the reaction mixture to conventional HPLC to detect and quantify cyclotetrasaccharide formed in the resulting mixture. In the present invention, one unit activity of forming cyclotetrasaccharide from partial starch hydrolyzates is defined as the enzyme amount that forms one micromole of cyclotetrasaccharide per minute under the above conditions.

[0037] In addition to the above-mentioned preparations from microorganisms,  $\alpha$ -isomaltosyl-transferring enzyme and  $\alpha$ -isomaltosylglucosaccharide-forming enzyme can be also obtained by the recombinant DNA technology. The same applicant as the present invention disclosed the nucleotide sequences of DNAs which encode the  $\alpha$ -isomaltosyl-transferring enzyme and  $\alpha$ -isomaltosylglucosaccharide-forming enzyme from Strain C11, FERM BP-7144, in Japanese Patent Application Nos. 350,142/2000 and 5,441/2001. As disclosed in these specifications, each of the above nucleotide sequences includes a nucleotide sequence of a coding region, which corresponds to a precursor of each of the enzymes having a signal peptide at the N-terminus, and those in the 5'- and 3'-non-translational regions. In the sequence listing of the present specification, SEQ ID NO:1 represents a nucleotide sequence of a coding region corresponding to a precursor of  $\alpha$ -isomaltosyl-transferring enzyme from Strain C11 disclosed in Japanese Patent Application No. 350,142/2000, and SEQ ID NO:2 represents a nucleotide sequence of a coding region corresponding to a precursor of  $\alpha$ -isomaltosylglucosaccharide-forming enzyme from Strain C11 disclosed in Japanese Patent Application No. 5,441/2001. With reference to these nucleotide sequences, both of the above enzymes can be prepared by using conventional recombinant DNA technologies such as a DNA cloning method, site-directed mutagenesis, transformation of microorganisms, and artificial expression method of DNAs. Conventional recombinant DNA technologies are, for example, described in detail in "Molecular cloning, A LABORATORY MANUAL, THIRD EDITION" by J. Sambrook, published by Cold Spring Harbor Laboratory Press, 2001.

#### 2.1.2. Preparation of cyclotetrasaccharide using $\alpha$ -isomaltosyl-transferring enzyme and $\alpha$ -isomaltosylglucosaccharide-forming enzyme

[0038] In preparing cyclotetrasaccharide from a substrate such as partial starch hydrolyzates by using  $\alpha$ -isomaltosyl-transferring enzyme and  $\alpha$ -isomaltosylglucosaccharide-forming enzyme, the former enzyme is allowed to act on a substrate, usually, in an aqueous solution form, after the action of or under the coaction of the latter enzyme. The coaction of the above enzymes is relatively preferable in view of the production efficiency of cyclotetrasaccharide. Examples of the substrates used in this method are saccharides having a glucose polymerization degree of at least two and the  $\alpha$ -1,4 glucosyl bond as a linkage at their non-reducing ends; maltooligosaccharides, maltodextrins, amylopectins, amyloses, amylopectins, soluble starches, liquefied starches, gelatinized starches, and glycogens. Considering the production cost, terrestrial starches such as corn, wheat, and rice; and subterranean starches such as potato, sweet potato, and tapioca are preferably used as starting materials. Both of the enzymes are preferably allowed to act on liquefied starches prepared by allowing liquefying-type amylases to act on suspensions of the above starches or heating the suspensions under acid conditions. The lower the "DE" (dextrose equivalent) of liquefied starch, the higher the yield of cyclotetrasaccharide becomes. The DE is usually 20 or lower, preferably, 12 or lower, and more preferably, five or lower. Prior to or in parallel with the action of  $\alpha$ -isomaltosyl-transferring enzyme and  $\alpha$ -isomaltosylglucosaccharide-forming enzyme on liquefied starch, debranching enzymes such as pullulanase or isoamylase can be advantageously used because they may increase the yield of cyclotetrasaccharide.

[0039] The concentration of substrates is not specifically restricted as long as cyclotetrasaccharide is formed. The higher the concentration, the higher the yield of cyclotetrasaccharide per batch becomes; usually, it is 0.1 % (w/w) or higher, preferably, one percent (w/w) or higher, d.s.b. Though substrates can be used in a solution form with a concentration over their water solubility, the concentration is preferably set to 40% (w/w) or lower, preferably, 35% (w/w) or lower, d.s.b., to ease handlings.

[0040] The reaction condition is not specifically restricted as long as cyclotetrasaccharide is formed. For example, any temperatures of from ambient temperature to 50°C, preferably, 30°C to 45°C, can be suitably used; and any pHs of from 4.5 to 8, preferably, from 5.5 to 7 can be preferably used. Metal ions such as  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$ , which stabilize



any of the enzymes used, can be advantageously coexisted in a reaction mixture. The reaction time can be arbitrarily set in view of the reaction progress, depending on the amount of the enzymes used.

[0041] If necessary, other saccharide transferring enzymes can be advantageously used when  $\alpha$ -isomaltosyl-transferring enzyme and  $\alpha$ -isomaltosylglucosaccharide-forming enzyme are allowed to act on a substrate. For example, the combination use of cyclomaltodextrin glucanotransferase may increase the production yield of cyclotetrasaccharide as compared with the case without the combination use.

[0042] As an enzyme agent used as  $\alpha$ -isomaltosyl-transferring enzyme and  $\alpha$ -isomaltosylglucosaccharide-forming enzyme to be allowed to act on a substrate, any microorganism which produces both the enzymes can be used. To use microorganisms as such an enzyme agent, for example, Strain C9, FERM BP-7143, and Strain C11, FERM BP-7144, which are capable of forming both the enzymes, are cultured and proliferated up to reach the desired cell density under their proliferation conditions. As the culture conditions for the above microorganisms, the above ones for forming enzymes can be arbitrarily used. The resulting cultures can be allowed to act on substrates similarly as in the above enzyme agent.

[0043] The reaction mixtures thus obtained contain cyclotetrasaccharide and they can be used intact as cyclotetrasaccharide solutions or used after purification. To purify cyclotetrasaccharide, conventional purification methods for saccharides can be appropriately employed. Examples of such are decoloration with activated charcoal; desalting with ion-exchange resins in H- and OH-forms; fractionation by column chromatography using an ion-exchange resin, activated charcoal, and silica gel (usually called "chromatography"); separation sedimentation using organic solvents such as alcohol and acetone; separation using membranes with appropriate separability; and decomposition and treatment to remove coexisting or remaining other saccharides, for example, enzymatic treatment with amylases such as  $\alpha$ -amylase,  $\beta$ -amylase, and glucoamylase, and  $\alpha$ -glucosidase, fermentation treatment with yeasts, and alkaline treatment. An appropriate combination use of the above purification methods advantageously increase the purity of cyclotetrasaccharide. The resulting purified cyclotetrasaccharide and saccharide compositions containing the same can be prepared into the desired form of a solution, syrup, block, powder, granule, crystal, etc., by applying thereunto an appropriate combination of treatments such as concentration, crystallization, drying, pulverization, and dissolution.

[0044] The above outlines the process for producing cyclotetrasaccharide, which uses  $\alpha$ -isomaltosyl-transferring enzyme and  $\alpha$ -isomaltosylglucosaccharide-forming enzyme in combination. In the method of using only  $\alpha$ -isomaltosyl-transferring enzyme (the above-mentioned process for producing cyclotetrasaccharide (2)), such an enzyme is prepared similarly as above and then allowed to act on  $\alpha$ -isomaltosylglucosaccharide such as panose commercialized or prepared in a usual manner, and optionally the formed cyclotetrasaccharide can be further purified similarly as above.

## 2.2. Enzyme which transfers glycosyl group to cyclotetrasaccharide

[0045] Any enzymes can be used in the process of the present invention independently of their unrequisite actions and origins other than the ability of forming the above-identified branched cyclotetrasaccharides, represented by Formula 1, by transferring a glycosyl group from monosaccharides, oligosaccharides, or polysaccharides (hereinafter, these saccharides are called "donors of glycosyl group"). Examples of such enzymes are cyclomaltodextrin glucanotransferase,  $\alpha$ -isomaltosyl-transferring enzyme,  $\alpha$ -isomaltosylglucosaccharide-forming enzyme,  $\beta$ -galactosidase,  $\alpha$ -galactosidase, and lysozyme. In terms of the transferring of a glycosyl group to cyclotetrasaccharide (the expression of "transfer of glycosyl group" may be abbreviated as "glycosyl transfer", hereinafter), the properties of each enzymes are briefly explained in the below:

[0046] Cyclomaltodextrin glucanotransferase (EC 2.4.1.19) usually transfers a glycosyl group from, as a donor of glycosyl group, a saccharide having the  $\alpha$ -1, 4 glucosyl bond as a linkage and having a glucose polymerization degree of at least two, such as maltooligosaccharide, maltodextrin, amylopectin, amylose, amylopectin, soluble starch, liquefied starch, gelatinized starch, or glycogen; and usually forms the branched cyclotetrasaccharides as in the first example of the aforesaid paragraph "1. Branched cyclotetrasaccharides".

[0047]  $\alpha$ -Isomaltosyl-transferring enzyme transfers a glycosyl group from, as a donor of glycosyl group,  $\alpha$ -isomaltosylglucosaccharides such as panose to cyclotetrasaccharide and usually forms the branched cyclotetrasaccharides as in the second example of the aforesaid paragraph "1. Branched cyclotetrasaccharides", particularly, those represented by Chemical formulae 3 and 4.

[0048]  $\alpha$ -Isomaltosylglucosaccharide-forming enzyme usually forms saccharides, which have the  $\alpha$ -1,4 glucosyl bond as a linkage and a glucose polymerization degree of at least three such as maltooligosaccharide, maltodextrin, amylopectin, amylose, amylopectin, soluble starch, liquefied starch, gelatinized starch, or glycogen; and usually forms the branched cyclotetrasaccharides represented by Formula 1.

[0049]  $\beta$ -Galactosidase (EC 3.2.1.23) usually transfers a glucosyl group from lactose as a donor of glycosyl group to cyclotetrasaccharide and usually forms the branched cyclotetrasaccharides as in the third and forth examples of the above paragraph "1. Branched cyclotetrasaccharides". Depending on the origin of  $\beta$ -galactosidase used, the type or the composition of the formed branched cyclotetrasaccharides may differ. For example, the enzymes from the micro-

organisms of the species *Bacillus circulans* relatively efficiently form the branched cyclotetrasaccharides represented by Chemical Formula 6, while those from the microorganisms of the species *Aspergillus niger* form the branched cyclotetrasaccharides represented by Chemical Formulae 6 to 8.

[0050]  $\alpha$ -Galactosidase (EC 3.2.1.22) usually transfers a glycosyl group from melibiose as a donor of glycosyl group to cyclotetrasaccharide and usually forms branched cyclotetrasaccharides, particularly, those represented by Chemical Formula 9 as in the fifth example of the above paragraph "1. Branched cyclotetrasaccharides".

[0051] Lysozyme (EC 3.2.1.17) usually transfers to cyclotetrasaccharide a glycosyl group from oligosaccharides or polysaccharides, as a donor of a glycosyl group, such as N-acetylchitooligosaccharide and chitin, which are composed of N-acetylchitosamine (also known as N-acetylglucosamine) as a constituent saccharide and the  $\beta$ -1,4 glycosyl bond; and usually forms the branched cyclotetrasaccharides, particularly, those represented by Chemical Formula 10 as in the sixth example of the above paragraph "1. Branched cyclotetrasaccharides".

[0052] The above describes the transferring reactions that are mainly catalyzed by the above enzymes when they each independently act on cyclotetrasaccharide, however, combination use of two or more of them can form other branched cyclotetrasaccharides. For example, when cyclomaltodextrin glucanotransferase and  $\alpha$ -isomaltosyl-transferring enzyme are combinationally allowed to act on both cyclotetrasaccharide and an appropriate saccharide as a donor of glycosyl group, the branched cyclotetrasaccharides represented by Chemical Formula 5 will be formed. Another combination of the above enzymes may form different types of branched cyclotetrasaccharides. In addition to the above exemplified enzymes, saccharide-related enzymes such as kojibiose phosphorylase, disclosed in Japanese Patent Kokai No. 304,882/98 applied for by the same applicant as the present applicant, glycogen phosphorylase (EC 2.4.1.1), maltose phosphorylase (EC 2.4.1.8),  $\alpha$ -glucosidase (EC 3.2.1.20), oligo-1,6-glucosidase (EC 3.2.1.10), and  $\beta$ -glucosidase (EC 3.2.1.21) can be arbitrarily used in the process of the present invention as long as they transfer a glycosyl group from its donor to cyclotetrasaccharide and form the branched cyclotetrasaccharides represented by the above-mentioned Formula 1. Particularly, the above kojibiose phosphorylase can be advantageously used to meet its purpose because, depending on reaction conditions, it can transfer a glycosyl group from either glucose-1-phosphate, as a donor saccharide, or a glycosyl group to cyclotetrasaccharide and form the branched cyclotetrasaccharides represented by Formula 1, with the proviso that one or more of  $R_3$ ,  $R_6$ ,  $R_9$ , and  $R_{12}$  are oligoglucosyl groups having  $\alpha$ -1, 2-glucosyl bonds such as a glycosyl group and a kojibiosyl group.

[0053] All the above-exemplified enzymes are well known in the art and any of commercialized preparations thereof or those prepared by conventional reports on their preparations can be used in practicing the present invention.

### 2.3. Preparation of branched cyclotetrasaccharides from cyclotetrasaccharide

[0054] To produce the branched cyclotetrasaccharides of the present invention, an enzyme (hereinafter abbreviated as "a glycosyl-transferring enzyme" in this paragraph 2.3.) is firstly selected depending on the structure of the aimed branched cyclotetrasaccharides, and is obtained by purchasing a commercialized enzyme preparation of such an enzyme or by preparing the enzyme in a conventional manner. A suitable saccharide as a donor of glycosyl group is obtained by purchasing a commercialized product thereof or by preparing the donor in a conventional manner, depending on the properties of the enzymes used. The cyclotetrasaccharide used in the present invention is prepared according to any of the methods described in the above paragraph 2.1.

[0055] Using a glycosyl-transferring enzyme and any of the above-mentioned substrates, i.e., cyclotetrasaccharide and a donor of glycosyl group, a mixture of substrates usually in the form of an aqueous solution is provided and then admixed with the enzyme to effect enzymatic reaction for forming the desired branched cyclotetrasaccharides in the resulting reaction mixture. The reaction conditions for the glycosyl-transferring enzyme are not specifically restricted as long as the desired branched cyclotetrasaccharides are formed. In practicing the enzymatic reaction in an aqueous system, though it varies depending on the water solubilities of substrates used at their reaction temperatures, the concentrations of substrates, i.e., the one of cyclotetrasaccharide is usually set to 1 to 40% (w/w), preferably, 5 to 35% (w/w); and the one of the donor of glycosyl group is set to the highest possible level but within the range that the donor dissolves therein, usually, in an amount of at least a half time of, preferably, at least the same as, and more preferably, at least two times of that of cyclotetrasaccharide. The reaction temperatures and pHs are arbitrarily selected in view of the enzymological properties of the glycosyl-transferring enzymes used as long as they do not completely inactivate the enzymes during their enzymatic reactions. The amount of enzymes is arbitrarily selected to yield the desired product at the end of enzymatic reaction depending on the substrate concentration and the reaction time used.

[0056] Though the resulting reaction mixture with branched cyclotetrasaccharides can be used intact as a saccharide composition containing the same, it is usually purified from the mixture before use. The branched cyclotetrasaccharides are purified according to conventional methods: Decoloration with an activated charcoal and desalting with ion-exchange resins in H- and OH-forms can be arbitrarily used. If necessary, the degree of purification of the desired branched cyclotetrasaccharides can be advantageously increased by an appropriate combination of fractionation by column chromatography using ion-exchange resins, activated carchols, and silica gels; fractional precipitation using organic

solvents such as alcohol and acetone; separation using membranes with an adequate separability; and other treatments of decomposing and removing the coexisting or remaining other saccharides, for example, enzymatic treatments with amylases such as  $\alpha$ -amylase,  $\beta$ -amylase, and glucoamylase, and  $\alpha$ -glucosidase, fermentations with yeasts, and alkaline treatments. The resulting purified branched cyclotetrasaccharide(s) and saccharide compositions containing the same can be treated with an appropriate combination of treatments such as concentration, crystallization, drying, pulverization, and dissolution, and optionally mixed with an appropriate saccharide other than the branched cyclotetrasaccharides of the present invention into the desired products in the form of a solution, syrup, block, crystalline powder containing hydrous- and/or anhydrous-crystals, amorphous powder, granule, isolated crystal, or molasses.

[0057] In the reaction to form cyclotetrasaccharide via the action of  $\alpha$ -isomaltosyl-transferring enzyme and  $\alpha$ -isomaltosylglucosaccharide-forming enzyme, or the action of  $\alpha$ -isomaltosyl-transferring enzyme on  $\alpha$ -isomaltosyl glucosaccharide, as shown in the above paragraph 2.1.2., the branched cyclotetrasaccharides of the present invention are formed as by-products in different yields depending on the reaction conditions used. Among the branched cyclotetrasaccharides, main components are those represented by Chemical Formula 1, and those in the second example of the above paragraph "1. Branched cyclotetrasaccharides", and those of Chemical Formulae 3, 4, and 5. Therefore, to meet the object, the branched cyclotetrasaccharides of the present invention can be obtained by separating from cyclotetrasaccharide in their reaction mixture obtained after the action of the aforesaid both enzymes or the sole use of  $\alpha$ -isomaltosyl-transferring enzyme.

### 3. Use of branched cyclotetrasaccharides

[0058] Since having a common basic structure, the branched cyclotetrasaccharides of the present invention usually have substantially the same properties and functions as of cyclotetrasaccharide. Therefore, the branched cyclotetrasaccharides can be used for purposes similarly as in cyclotetrasaccharide. The following is a brief description of the uses of the branched cyclotetrasaccharides of the present invention which can be used in accordance with those of the cyclotetrasaccharide disclosed in Japanese Patent Application No. 234,937/2000 (International Publication No. WO 02/10,361 A1).

[0059] The branched cyclotetrasaccharides of the present invention are usually stable, non-reducing saccharides, which have a white powder form and a relatively low- or non-sweetness, refined taste. When mixed and processed with other materials, particularly, amino acids or materials containing amino acids such as oligopeptides and proteins, the branched cyclotetrasaccharides hardly induce the browning reaction, hardly cause undesirable smell, and hardly spoil the other materials mixed. Thus, the branched cyclotetrasaccharides of the present invention can be incorporated and used as materials or bases in many fields such as food products, cosmetics, and pharmaceuticals.

[0060] Since the branched cyclotetrasaccharides of the present invention have an inclusion ability, they effectively inhibit the volatilization and the deterioration of flavoring ingredients and effective ingredients, and quite satisfactorily, stably keep these ingredients. In this case, if necessary, the above stabilization by inclusion can be enhanced by the combination use of other cyclotetrasaccharides such as cyclodextrins, branched cyclodextrins, cyclodextrans, and cyclofractans. The cyclotetrasaccharides such as cyclodextrins should not be limited to those with the highest purity, and include those with a lower purity, for example, partial starch hydrolyzates rich in maltodextrins along with cyclodextrins can be arbitrarily used.

[0061] Since cyclotetrasaccharide is not hydrolyzed by amylase or  $\alpha$ -glucosidase, it is not assimilated and absorbed by living bodies when orally taken, hardly fermented by intestinal bacteria, and utilized as an aqueous dietary fiber with quite low calories. Also, since cyclotetrasaccharide is hardly assimilated by dental-carries-inducing bacteria, it can be used as a sweetener which does not substantially cause dental caries. Further, cyclotetrasaccharide also has a function of preventing the adhesion and solidification of solid materials within the oral cavity. The branched cyclotetrasaccharides of the present invention have the same basic structure as cyclotetrasaccharide and have a high utility as saccharides with a relatively low calorie and cariogenicity compared with conventional saccharides susceptible to fermentation by dental-carries inducing bacteria. The branched cyclotetrasaccharides of the present invention are non-poisonous, harmless saccharides, free from side effect, and useful as stable materials or bases, and when they are in the form of a crystalline product, they can be arbitrarily processed into tablets or sugar coated tablets in combination with binders such as pullulan, hydroxyethyl starch, or poly(vinylpyrrolidone). The branched cyclotetrasaccharides of the present invention have properties such as osmotic pressure-controlling ability, filling ability, gloss-imparting ability, moisture-retaining ability, viscosity-imparting ability, crystallization preventing ability of other saccharides, and insubstantial fermentability. Therefore, the branched cyclotetrasaccharides and the saccharide compositions comprising the same can be advantageously used in compositions such as food products, articles of taste including tobaccos and cigarettes, feeds, baits, cosmetics, and pharmaceuticals as saccharide seasonings, taste-improving agents, quality-improving agents, stabilizers, color-deterioration preventing agents, and fillers.

[0062] The branched cyclotetrasaccharides and the saccharide compositions comprising the same can be used intact as seasonings to give a refined taste, and if necessary, they can be used in combination with other sweeteners

such as a powdered starch hydrogenate, glucose, isomerized sugar, sugar, maltose, trehalose, honey, maple sugar, sorbitol, maltitol, dihydrochalcones, stevioside,  $\alpha$ -glycosylstevioside, extract from *Momordica grosvenori*, glycyrrhizin, thaumatin, L-aspartylphenylalanine methylester, saccharin, acesulfam K, sucralose, glycine, and alanine; or fillers such as dextrans, starches, and lactose. Particularly, the branched cyclotetrasaccharide and the saccharide compositions comprising the same can be preferably used as low-caloric or diet sweeteners in combination with one or more sweeteners such as *meso*-erythritol, xylitol, or maltitol; sweeteners with high sweetness such as  $\alpha$ -glycosylstevioside, thaumatin, L-aspartylphenylalanine methylester, saccharin, acesulfam K, and sucralose.

[0063] The branched cyclotetrasaccharides and the saccharide compositions comprising the same can be arbitrarily used intact or optionally mixed with fillers, excipients, and binders; and then shaped into appropriate forms such as a granule, sphere, short stick/rod, sheet, cube, and tablet.

[0064] The refined taste of the branched cyclotetrasaccharides and the saccharide compositions comprising the same well harmonize with other materials having sour-, acid-, salty-, delicious-, astringent-, and bitter-tastes; and have a satisfactorily-high acid- and heat-tolerance. Thus, they can be favorably used as sweeteners, taste-improving agents, quality-improving agents, etc., in seasonings, for example, a soy sauce, powdered soy sauce, *miso*, "*funmatsu-miso*" (a powdered miso), "*moromi*" (a refined sake), "*hishio*" (a refined soy sauce), "*furikake*" (a seasoned fish meal), mayonnaise, dressing, vinegar, "*sanbai-zu*" (a sauce of sugar, soy sauce and vinegar), "*funmatsu-sushi-su*" (powdered vinegar for sushi), "*chuka-no-moto*" (an instant mix for Chinese dish), "*tentsuyu*" (a sauce for Japanese deep-fat fried food), "*mentsuyu*" (a sauce for Japanese vermicelli), sauce, catsup, "*yakiniku-no-tare*" (a sauce for Japanese grilled meat), curry roux, instant stew mix, instant soup mix, "*dashi-no-moto*" (an instant stock mix), mixed seasoning, "*mirin*" (a sweet sake), "*shin-mirin*" (a synthetic mirin), table sugar, and coffee sugar. Also, the cyclotetrasaccharide and the saccharide compositions comprising the same can be arbitrarily used to sweeten and improve the taste and quality of "*wagashi*" (Japanese cakes) such as "*senbei*" (a rice cracker), "*arare*" (a rice cake cube), "*okoshi*" (a millet-and-rice cake), "*gyuhi*" (a starch paste), "*mochi*" (a rice paste) and the like, "*manju*" (a bun with a bean-jam), "*uiro*" (a sweet rice jelly), "*an*" (a bean jam) and the like, "*yokan*" (a sweet jelly of beans), "*mizu-yokan*" (a soft adzuki-bean jelly), "*kingyoku*" (a kind of yokan), jelly, pao de Castella, and "*amedama*" (a Japanese toffee); Western confectioneries such as a bun, biscuit, cracker, cookie, pie, pudding, butter cream, custard cream, cream puff, waffle, sponge cake, doughnut, chocolate, chewing gum, caramel, nougat, and candy; frozen desserts such as an ice cream and sherbet; processed foods of fruit and vegetables such as a jam, marmalade, and "*toka*" (conserves); pickles and pickled products such as a "*fukujin-zuke*" (red colored radish pickles), "*bettara-zuke*" (a kind of whole fresh radish pickles), "*senmai-zuke*" (a kind of sliced fresh radish pickles), and "*rakkyo-zukce*" (pickled shallots); premixes for pickles and pickled products such as a "*takuan-zuke-no-moto*" (a premix for pickled radish), and "*hakusai-zuke-no-moto*" (a premix for fresh white rape pickles); meat products such as a ham and sausage; fish meat products such as a fish ham, fish sausage, "*kam-aboko*" (a steamed fish paste), "*chikuwa*" (a kind of fish paste), and "*tenpura*" (a Japanese deep-fat fried fish paste); "*chinmi*" (relish) such as a "*uni-no-shiokara*" (salted guts of sea urchin), "*ika-no-shiokara*" (salted guts of squid), "*su-konbu*" (processed tangle), "*saki-surume*" (dried squid strips), "*fugu-no-mirin-boshi*" (a dried mirin-seasoned swellfish), seasoned fish flour such as of Pacific cod, sea bream, shrimp, etc; "*tsukudani*" (foods boiled down in soy sauce) such as those of lavers, edible wild plants, dried squids, small fishes, and shellfishes; daily dishes such as a "*nimame*" (cooked beans), potato salad, and "*konbu-maki*" (a tangle roll); milk products; canned and bottled products such as those of meat, fish meat, fruit, and vegetable; alcoholic beverages such as a synthetic sake, fermented liquor, sake, fruit wine, sparkling alcoholic beverage, beer; soft drinks such as a coffee, cocoa, juice, carbonated beverage, lactic acid beverage, and beverage with lactic acid bacteria; instant food products such as instant pudding mix, instant hot cake mix, instant juice or soft drink, instant coffee, "*sokuseki-shiruko*" (an instant mix of adzuki-bean soup with rice cake), and instant soup mix; and other foods and beverages such as a food for babies, food for therapy, health/tonic drink, peptide food, and frozen food. The branched cyclotetrasaccharides and the saccharide compositions comprising the same can be arbitrarily used to improve the taste preference and property of feeds and pet foods for animals and pets such as domestic animals, poultry, honey bees, silk worms, and fishes; and also they can be arbitrary used as a taste preference-improving agent, taste-improving agent, flavor-imparting agent, quality-improving agent, and stabilizer in other tastable products, cosmetics, and pharmaceuticals in a solid, paste, or liquid form such as a tobacco, cigarette, tooth paste, lipstick, rouge, lip cream, internal liquid medicine, tablet, troche, cod liver oil drop, cachou, oral refreshment, and gargle. When used as a quality-improving agent or stabilizer, the branched cyclotetrasaccharides and the saccharide compositions comprising the same can be arbitrarily used in biologically active substances susceptible to lose their active ingredients, as well as health foods and pharmaceuticals containing such biologically active substances. Examples of such biologically active substances are liquid preparations containing lymphokines such as  $\alpha$ -,  $\beta$ - and  $\gamma$ -interferons, tumor necrosis factor-  $\alpha$  (TNF-  $\alpha$ ), tumor necrosis factor-  $\beta$  (TNF-  $\beta$ ), macrophage migration inhibitory factor, colony-stimulating factor, transfer factor, and interleukin 2; liquid preparations containing hormones such as insulin, growth hormone, prolactin, erythropoietin, and follicle-stimulating hormone; liquid preparations containing biologically active substances such as BCG vaccine, Japanese encephalitis vaccine, measles vaccine, live polio vaccine, smallpox vaccine, tetanus toxoid, Trimeresurus antitoxin, and human immunoglobulin; liquid preparations containing

antibiotics such as penicillin, erythromycin, chloramphenicol, tetracycline, streptomycin, and kanamycin sulfate; liquid preparations containing vitamins such as thiamine, riboflavin, L-ascorbic acid, cod liver oil, carotenoid, ergosterol, and tocopherol; liquid preparation containing highly unsaturated fatty acids and ester derivatives thereof such as EPA, DHA, and arachidonic acid, or containing enzymes such as lipase, elastase, urokinase, protease,  $\beta$ -amylase, isoamylase, glucanase, and lactase; extracts such as ginseng extract, snapping turtle extract, chlorella extract, aloe extract, and propolis extract; biologically active substances such as royal jelly; and pastes with alive viruses, lactic acid bacteria or yeasts. By applying to the above biologically active substances, the branched cyclotetrasaccharides and the saccharide compositions containing the same to the above biologically active substances facilitate the production of stabilized, high-quality health foods and pharmaceuticals in the form of a liquid, paste, or solid with less fear of losing or inactivating the effective ingredients and activities of the substances.

**[0065]** The methods for incorporating the branched cyclotetrasaccharides or the saccharide compositions containing the same into the aforesaid compositions are those which can incorporate them into a variety of compositions before completion of their processings. For such purposes, the following conventional methods such as mixing, kneading, dissolving, melting, soaking, penetrating, dispersing, applying, coating, spraying, injecting, crystallizing, and solidifying can be appropriately selected. The percentage of the branched cyclotetrasaccharides or the saccharide compositions containing the same to the final compositions is usually at least 0.1%, desirably, at least 1%, d.s.b.

**[0066]** In addition to the above uses similar to those for cyclotetrasaccharide, the branched cyclotetrasaccharides of the present invention may exhibit an activity of growing bifid bacteria and it can be used as a factor for such purpose when incorporated into foods, beverages, health foods, health food supplements, and pharmaceuticals. In this case, other saccharides, having an activity of growing bifid bacteria, such as lactosucrose (4- $\beta$ -D-galactosylsucrose), N-acetyl-D-chitosamine (N-acetyl-D-glucosamine), and lactulose can be advantageously used together. Since the branched cyclotetrasaccharides of the present invention has a function of preventing crystallization of cyclotetrasaccharide in an aqueous solution, it can be used as a crystallization-preventing agent for such purpose. For example, when the branched cyclotetrasaccharides or the saccharide compositions containing the same of the present invention are added to an aqueous solution, containing cyclotetrasaccharide alone or in combination with another reducing saccharide(s) such as glucose, maltose and panose, obtained by any of the above methods, the resulting solution can be concentrated into a supersaturated solution of cyclotetrasaccharide. Further, the above solution can be used after hydrogenation by reducing saccharides contained therein into sugar alcohols, if necessary. The high cyclotetrasaccharide content solutions thus obtained can be more efficiently stored in tanks and transported by pumps and tank lorries compared with solutions free of the branched cyclotetrasaccharides of the present invention. Thus, the branched cyclotetrasaccharides of the present invention are remarkably useful in industrial handlings of cyclotetrasaccharide.

**[0067]** The following experiments explain the present invention in more detail:

#### Experiment 1: Isolation and identification of cyclotetrasaccharides from culture of microorganism

**[0068]** A liquid culture medium, consisting of 5% (w/v) of panose, 1.5% (w/v) of "ASAHIMEAST™", a yeast extract commercialized by Asahi Breweries, Ltd., Tokyo, Japan, 0.1% (w/v) of dipotassium phosphate, 0.06% (w/v) of sodium dihydrogen phosphate dodecahydrate, 0.05% (w/v) magnesium sulfate heptahydrate, and water was placed in a 500-ml Erlenmeyer flask in an amount of 100 ml, was sterilized by autoclaving at 121°C for 20 min, cooled, and then seeded with a seed culture of *Bacillus globisporus* C9 strain, FERM BP-7143, followed by culturing under rotary-shaking conditions at 27°C and 230 rpm for 48 hours and centrifuging the resulting culture to remove cells to obtain a supernatant. The supernatant was autoclaved at 120°C for 15 min and then cooled, and the resulting insoluble substances were removed by centrifugation to obtain a supernatant. A non-reducing saccharide, which was positive on the sulfuric acid-methanol method and negative on the diphenylamine-aniline method, was observed in this supernatant.

**[0069]** About 90 ml of the supernatant after the autoclaving was adjusted to pH 5.0 and 45°C and then incubated for 24 hours after the addition of 1,500 units per gram of solids of "TRANSGLUCOSIDASE L AMANO™", an  $\alpha$ -glucosidase commercialized by Amano Pharmaceutical Co., Ltd., Aichi, Japan, and 75 units per gram of solids of "GLUCOTEAM™", a glucoamylase commercialized by Nagase Biochemicals, Ltd., Kyoto, Japan. Thereafter, the resulting mixture was adjusted to pH 12 by the addition of sodium hydroxide and boiled for two hours to decompose the reducing sugars in the supernatant. After removing insoluble substances by filtration, the filtrate was decolorized and desalted with "DIAION PK218™" and "DIAION WA30™", ion-exchange resins commercialized by Mitsubishi Chemical Industries, Ltd., Tokyo, Japan, and further desalted with "DIAION SK-1B™", a cation exchange resin commercialized by Mitsubishi Chemical Industries, Ltd., Tokyo, Japan, and "AMBERLITE IRA411™", an anion exchange resin commercialized by Japan Organo Co., Ltd., Tokyo, Japan, followed by filtrating with a membrane, concentrated by an evaporator, and lyophilized *in vacuo* to obtain about 0.5 g solid of a non-reducing saccharide powder.

**[0070]** The purity of the non-reducing saccharide powder was analyzed on high-performance liquid chromatography (abbreviated as "HPLC" hereinafter). HPLC was carried out using "SHOWDEX KS-801 column™", Showa Denko K. K., Tokyo, Japan, at a column temperature of 60°C and a flow rate of 0.5 ml/min of water, and using "RI-8012™", a



differential refractometer commercialized by Tosoh Corporation, Tokyo, Japan. As shown in FIG.1, a single peak was detected at an elution time of 10.84 min, revealing that the saccharide had a high purity of at least 99.9%.

[0071] Mass analysis by fast atom bombardment mass spectrometry (called "FAB-MS") of the non-reducing saccharide, obtained by the aforesaid method, significantly detected a proton-addition-molecular ion with a mass number of 649, revealing that the saccharide had a mass number of 648.

[0072] The above non-reducing saccharide was hydrolyzed with sulfuric acid and then analyzed for sugar composition by conventional gas chromatography. As a result, only D-glucose was detected, revealing that the saccharide was cyclotetrasaccharide composed of four moles of D-glucose in view of the above mass number and non-reducibility.

[0073] Nuclear magnetic resonance analysis (called "NMR") of the non-reducing saccharide gave a  $^1\text{H}$ -NMR spectrum in FIG. 2 and a  $^{13}\text{C}$ -NMR spectrum in FIG. 3. These spectra were compared with those of known saccharides and revealed that they coincided with those of cyclotetrasaccharide as disclosed by Gregory L. Cote et al. in *European Journal of Biochemistry*, Vol. 226, pp. 641-648 (1994).

[0074] Based on these results, the non-reducing saccharide isolated in the above method was identified with cyclotetrasaccharide, i.e., cyclo{ $\rightarrow 6$ }- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 3)- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 3)- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ )}.

#### Experiment 2: $\alpha$ -Isomaltosyl-transferring enzyme and $\alpha$ -isomaltosylglucosaccharide-forming enzyme

##### Experiment 2-1: Enzyme preparation containing $\alpha$ -isomaltosyl-transferring enzyme and $\alpha$ -isomaltosylglucosaccharide-forming enzyme

[0075] A liquid culture medium, consisting of 4.0% (w/v) of "PINE-DEX #4<sup>TM</sup>", a partial starch hydrolyzate commercialized by Matsutani Chemical Ind., Tokyo, Japan, 1.8% (w/v) of "ASAHIMEAST<sup>TM</sup>", a yeast extract commercialized by Asahi Breweries, Ltd., Tokyo, Japan, 0.1% (w/v) of dipotassium phosphate, 0.06% (w/v) of sodium dihydrogen phosphate dodecahydrate, 0.05% (w/v) magnesium sulfate heptahydrate, and water, was placed in 500-ml Erlenmeyer flasks in respective volumes of 100 ml, sterilized by autoclaving at 121°C for 20 min, cooled, and then seeded with a stock culture of *Bacillus globisporus* C9 strain, FERM BP-7143, followed by culturing under rotary-shaking conditions at 27°C and 230 rpm for 48 hours for a seed culture.

[0076] About 20 L of a fresh preparation of the same liquid culture medium as used in the above seed culture was placed in a 30-L fermenter, sterilized by heating, and then cooled to 27°C and inoculated with 1% (v/v) of the seed culture, followed by culturing at 27°C and a pH of 6.0-8.0 for 48 hours under aeration-agitation conditions. The resulting culture was centrifuged at 10,000 rpm for 30 min to obtain about 18 L of a supernatant. The obtained supernatant had an activity of about 1.5 units/ml of  $\alpha$ -isomaltosyl-transferring enzyme, an activity of about 0.45 unit/ml of  $\alpha$ -isomaltosylglucosaccharide-forming enzyme, and an activity of about 0.95 unit/ml of cyclotetrasaccharide-forming enzyme.

[0077] The supernatant was concentrated to give a volume of two liters by using "API-2013<sup>TM</sup>", a membrane for ultrafiltration commercialized by Asahi Kasei Corporation, Tokyo, Japan, to obtain an enzyme preparation containing  $\alpha$ -isomaltosylglucosaccharide-forming enzyme and  $\alpha$ -isomaltosyl-transferring enzyme. The enzyme preparation had about 8.5 units/ml of cyclotetrasaccharide-forming activity.

##### Experiment 2-2: Purified $\alpha$ -isomaltosyl-transferring enzyme

[0078] About 18 L of the culture supernatant of *Bacillus globisporus* C9 strain in Experiment 2-1, having 26,900 units of  $\alpha$ -isomaltosyl-transferring enzyme, was salted out with 80% saturated ammonium sulfate at 4°C for 24 hours. The formed sediments were collected by centrifugation at 10,000 rpm for 30 min, dissolved in 10 mM phosphate buffer (pH 7.5), and dialyzed against a fresh preparation of the same buffer to collect a dialyzed inner solution.

[0079] The dialyzed inner solution was fed to a column packed with 1,000 ml of "SEPABEADS FP-DA13<sup>TM</sup>" gel, an ion-exchange resin commercialized by Mitsubishi Chemical Industries, Ltd., Tokyo, Japan, followed by collecting non-adsorbed fractions.

[0080] The non-adsorbed fractions were pooled and dialyzed against 10 mM phosphate buffer (pH 7.0) with 1 M ammonium sulfate, and the dialyzed inner solution was collected and centrifuged to remove insoluble substances, and then fed to affinity column chromatography using 500 ml of "SEPHACRYL HR S-200<sup>TM</sup>", a gel commercialized by Amersham Corp., Div. Amersham International, Arlington Heights, IL, USA, followed by feeding thereunto a linear gradient decreasing from 1 M to 0 M of ammonium sulfate and collecting fractions, having an  $\alpha$ -isomaltosyl-transferring enzyme activity, eluted at around 0 M ammonium sulfate.

[0081] The fractions purified on the above affinity column chromatography were pooled and dialyzed against 10 mM phosphate buffer (pH 7.0) containing 1 M ammonium sulfate. The dialyzed inner solution was centrifuged to remove insoluble substances, and the resulting supernatant was fed to hydrophobic chromatography using 350 ml of "BUTYL-TOYOPEARL 650 M", a gel commercialized by Tosoh Corporation, Tokyo, Japan, followed by feeding there-

unto a linear gradient decreasing from 1 M to 0 M of ammonium sulfate and collecting fractions, having an  $\alpha$ -isomaltosyl-transferring enzyme activity, eluted at around 0.3 M ammonium sulfate.

[0082] The fractions purified in the above hydrophobic chromatography were pooled and dialyzed against 10 mM phosphate buffer (pH 7.0) containing 1 M ammonium sulfate. The dialyzed inner solution was centrifuged to remove insoluble substances, and the resulting supernatant was fed to affinity column chromatography again under the same conditions as above, followed by collecting a fraction with the enzyme activity.

[0083] The fraction, purified twice on the affinity column chromatography, was subjected to SDS-PAGE using a 7.5% (w/v) of polyacrylamide gel, resulting in a single protein band at a position corresponding to a molecular weight of about  $112,000 \pm 20,000$  daltons. The specific activity of the enzyme in the fraction was calculated based on its enzyme activity and protein quantitative analysis, revealing that it had a specific activity of about 26.9 units/mg protein. Thus, a purified  $\alpha$ -isomaltosyl-transferring enzyme specimen was obtained.

#### Experiment 2-3: Purified $\alpha$ -isomaltosylglucosaccharide-forming enzyme

[0084] About 18 L of a culture supernatant of *Bacillus globisporus* C9 strain obtained by the method in Experiment 2-1, having 8,110 units of an  $\alpha$ -isomaltosylglucosaccharide-forming enzyme, was subjected to salting-out with an 80% saturation solution of ammonium sulfate, dialyzed, and purified on ion-exchange resin according to method in Experiment 2-2.

[0085] The fractions purified on the ion-exchange resin were pooled and dialyzed against 10 mM phosphate buffer (pH 7.0) with 1 M ammonium sulfate. The dialyzed inner solution was centrifuged to remove insoluble substances, and fed to affinity column chromatography using 500 ml of "SEPHACRYL HR S-200", a gel commercialized by Amersham Corp., Div., Amersham International, Arlington Heights, IL, USA. The elution of the enzyme was carried out using a linear gradient decreasing from 1 M to 0 M of ammonium sulfate and subsequently a linear gradient increasing from 0 mM to 100 mM of maltotetraose, followed by collecting fractions eluted at around 30 mM maltotetraose with an  $\alpha$ -isomaltosylglucosaccharide-forming enzyme activity.

[0086] The fractions, purified on the above affinity column chromatography, were pooled and dialyzed against 10 mM phosphate buffer (pH 7.0) containing 1 M ammonium sulfate. The dialyzed inner solution was centrifuged to remove insoluble substances, and the resulting supernatant was fed to hydrophobic column chromatography using 350 ml of "BUTYL-TOYOPEARL 650 M", a gel commercialized by Tosoh Corporation, Tokyo, Japan, followed by feeding thereunto a linear gradient decreasing from 1 M to 0 M of ammonium sulfate and collecting fractions with an  $\alpha$ -isomaltosylglucosaccharide-forming enzyme activity eluted at around 0.3 M ammonium sulfate.

[0087] The fractions, purified on the above hydrophobic chromatography, were pooled and dialyzed against 10 mM phosphate buffer (pH 7.0) containing 1 M ammonium sulfate. The dialyzed inner solution was centrifuged to remove insoluble substances, and the resulting supernatant was fed to affinity chromatography again under the same conditions as in the above, followed by collecting a fraction with the enzyme activity.

[0088] The above fraction was subjected to SDS-PAGE using a 7.5% (w/v) of a polyacrylamide gel and detected as a single protein band with a molecular weight of about  $140,000 \pm 20,000$  daltons. The specific activity of the enzyme in the fraction was calculated based on its enzyme activity and protein quantitative analysis, revealing that it had a specific activity of about 13.6 units/mg protein. Thus, a purified specimen of  $\alpha$ -isomaltosylglucosaccharide-forming enzyme was obtained.

[0089] Though the above Experiments 2-1 to 2-3 show the data on preparations of enzymes from *Bacillus globisporus* C9 strain, such enzymes can be also obtained from *Bacillus globisporus* C11 strain, FERM BP-7144, in accordance with the above methods. The following are the properties of enzymes purified from *Bacillus globisporus* C11 strain in accordance with Experiments 2-1 to 2-3:

(A)  $\alpha$ -Isomaltosyl-transferring enzyme Molecular weight on SDS-PAGE:  $102,000 \pm 20,000$  Daltons Specific activity: About 26.9 units/mg protein

(B)  $\alpha$ -Isomaltosylglucosaccharide-forming enzyme Molecular weight on SDS-PAGE:  $137,000 \pm 20,000$  Daltons Specific activity: About 13.4 units/mg protein

#### Experiment 3: Production of cyclotetrasaccharide by enzymatic action on partial starch hydrolyzate and branched cyclotetrasaccharide as a by-product

##### Experiment 3-1: Enzymatic reaction

[0090] 3.7 kg of "PINE-DEX #100™", a partial starch hydrolyzate commercialized by Matsutani Chemical Ind., Tokyo, Japan, was dissolved in 35 L of 10 mM sodium acetate (pH 6.0). To the resulting solution was added about 17,500 units of cyclotetrasaccharide forming activity of an enzyme preparation, obtained by the method in Experiment 2-1,

and enzymatically reacted at 30°C for two days, followed by boiling for 20 min to inactivate the remaining enzyme. The resulting mixture was cooled to 45°C and admixed with 11g (137,500 units) of "NEO-SPITASE PK2™", an  $\alpha$ -amylase specimen commercialized by Nagase Biochemicals, Ltd., Kyoto, Japan, and 44 g (140,800 units) of "GLUCOZYME™", a glucoamylase specimen commercialized by Nagase Biochemicals, Ltd., Kyoto, Japan, and then adjusted to pH 6.0, followed by enzymatically reacting at 45°C for one day. The reaction mixture was boiled for 20 minutes to inactivate the remaining enzymes, and then cooled and filtered in a usual manner to obtain a filtrate. The filtrate was concentrated to give a solid concentration of about 16% (w/w) by using a reverse osmosis membrane. The resulting concentrate was subjected in a usual manner to decoloration, desalting, filtration, and concentration to obtain about 6.1 kg of a saccharide solution with a solid content of about 3.5 kg.

**[0091]** The saccharide solution was analyzed by the following HPLC by using both cyclotetrasaccharide, isolated by the method in Experiment 1, and known saccharides as a standard. HPLC was run using "CCPM", a chromatograph commercialized by Tosoh Corporation, Tokyo, Japan, "AQ-303 ODS", and a column with a diameter of 4.6 mm and a length of 25 cm commercialized by YMC Co., Ltd., Tokyo, Japan, at a column temperature of 40°C and a flow rate of 0.5 ml/min of water; and using "RI-8012™", a differential refractometer commercialized by Tosoh Corporation, Tokyo, Japan. Among the ingredients detected on this analysis, the data for those with a respectively-wide peak area were shown in Table 2 including their retention times, names, and relative values of peak areas.

Table 2

Retention time on HPLC (min*)	Name	Peak area**
10.5	Cyclotetrasaccharide	43.8%
19.7	Secondary Product 1	10.6%
24.7	Secondary Product 2	3.3%
49.9	Secondary Product 3	0.5%
58.2	Secondary Product 4	0.3%

\* All the retention times are approximate values.

\*\* Each value is a relative value when the sum of the detected peak areas is regarded as 100.

**[0092]** Upon the above HPLC, as a whole, there exists a tendency that the higher the molecular weight of a compound tested, the longer the retention time of the compound becomes. Thus, the results in Table 2 show that the enzymatic reaction of this experiment usually forms saccharides with a higher molecular weight than cyclotetrasaccharide, i.e., those which are composed of a larger number of saccharides than cyclotetrasaccharide, together with cyclotetrasaccharide.

#### Experiment 3-2: Preparation of cyclotetrasaccharides

**[0093]** 6.1 kg of a saccharide solution obtained by the method in Experiment 3-1 was fed to columns, consisting of ten columns, which each had a diameter of 13.5 cm and a length of 160 cm and which were cascaded in series and packed with about 225 L of "AMBERLITE CR-1310 (Na-form)™", an ion-exchange resin commercialized by Japan Organo Co., Ltd., Tokyo, Japan; and chromatographed at a flow rate of about 45 L/h of water and a column temperature of 60°C. The resulting elute was fractionated and analyzed for saccharide composition on HPLC as described in Experiment 3-1 in such a manner of pooling fractions relatively rich in cyclotetrasaccharide into a saccharide solution with a solid content of 1,530 g. HPLC analysis of the saccharide solution conducted under the same conditions as above and the data calculated based on the results on the peak areas of HPLC revealed that the pooled fraction, i.e., a high cyclotetrasaccharide content fraction, contained 79.8% cyclotetrasaccharide of 79.8% and 6.1% isomaltose to the total sugar contents.

**[0094]** The high cyclotetrasaccharide content fraction with a solid content of 1,310 g was adjusted to pH 5.0 and 50°C, and then incubated for 20 hours after admixed with 1,000 units/g solids of "TRANSGLUCOSIDASE L AMANO-OTM", an  $\alpha$ -glucosidase commercialized by Amano Pharmaceutical Co., Ltd., Aichi, Japan, and 60 units/g solids of "GLUCOTEAM™", a glucoamylase commercialized by Nagase Biochemicals, Ltd., Kyoto, Japan. After removing insoluble substances by filtration, the above reaction mixture was desalted with "DIAION PK218™", a cation exchange resin commercialized by Mitsubishi Chemical Industries, Ltd., Tokyo, Japan, and "AMBERLITE IRA411™", an anion exchange resin commercialized by Japan Organo Co., Ltd., Tokyo, Japan, followed by concentrating. The concentrate was fractionated according to the conditions used in the above chromatography to obtain a fraction with a cyclotetrasaccharide purity of at least 97%. The fractions were pooled and in a conventional manner decolored, desalted, filtered, and concentrated into a saccharide solution with a solid content of about 1,260 g. After adjusted to give a solid concentration of about 50% (w/w), the saccharide solution was placed in a cylindrical plastic vessel and cooled from 65°C



to 20°C over about 20 hours under gentle stirring conditions to effect crystallization. The formed crystals were collected by separation and dried at 60°C for three hours under normal pressure to obtain 544 g of a crystalline powder. The crystalline powder was of a crystalline cyclotetrasaccharide with a purity of 99.9% and a moisture content of 12.7%.

#### Experiment 3-3: Isolation of by-products

**[0095]** 6.1 kg of a saccharide solution obtained by the method in Experiment 3-1 was fractionated according to the chromatography as described in Experiment 3-2, and the resulting fractions were analyzed for saccharide composition on HPLC as described in Experiment 3-1. Fractions relatively rich in the by-products 1 and 2 were pooled for Fraction 1, while fractions relatively rich in the by-products 3 and 4 were pooled for Fraction 2. Fractions 1 and 2 had solid contents of 320g and 150 g, respectively. Based on the peak areas of Fractions 1 and 2 on HPLC, their saccharide compositions were determined, revealing that Fraction 1 contained 47.9% of the by-product 1 and 14.9% of the by-product 2 to the total sugars and Fraction 2 contained components, which contained the by-products 3 and 4 had a retention time longer than that of by-product 2 when measured on the above HPLC, in an amount of at least 25% to the total sugars.

**[0096]** Fraction 1 was kept at a pH of 11 or higher by the addition of sodium hydroxide and heated at 95°C or higher for one hour to decompose reducing saccharides, followed by decoloring, desalting, filtering, and concentrating in a conventional manner. An adequate amount of the concentrate equal to a solid content of 50 g by weight was subjected to preparative liquid chromatography using "YMN-PACK ODS-A R355-15 S-15 120A", a preparative column commercialized by YMC Co., Ltd., Tokyo, Japan, and a purified, deionized water as a moving phase. Based on the HPLC analysis described in Experiment 3-1, the above chromatography yielded a fraction with a solid content of 20 g containing the by-product 1 with a purity of at least 97%, and another fraction with a solid content of five grams containing the by-product 2 with a purity of at least 96%.

**[0097]** Similarly as in Fraction 1, the above Fraction 2 was subjected to decomposition of reducing saccharides, followed by decoloring, desalting, filtering, and concentrating. An adequate amount of the concentrate equal to a solid content of 10 g by weight was subjected to preparative liquid chromatography by using preparative chromatography similarly as in Fraction 1. Based on the HPLC analysis described in Experiment 3-1, the above chromatography yielded a fraction with a solid content of 77 mg containing the by-product 3 with a purity of at least 97%, and another fraction with a solid content of 77 mg containing the by-product 4 with a purity of at least 97%.


#### Experiment 3-4: Identification of by-products

**[0098]** Fractions rich in the by-products 1 to 4 obtained in Experiment 3-3 were subjected to wholly or partly to the following analysis: (1) Mass number was determined by mass spectroscopy using the high-speed atom shocking method, (2) reducing power was determined by the Somogyi-Nelson method, (3) saccharide composition was determined by conventional gas chromatography to analyze constituent saccharides after hydrolysis with sulfuric acid, (4) biological analysis was conducted by the HPLC analysis described in Experiment 3-1 after treatment with "TRANSGLUCOSIDASE L AMANO™", an  $\alpha$ -glucosidase commercialized by Amano Pharmaceutical Co., Ltd., Aichi, Japan, (5) binding fashion was determined by a conventional methylation analysis, (6) specific rotation was measured in a conventional manner, and (7)  $^{13}\text{C}$ -NMR was done in a conventional manner. The results are as follows:

**[0099]** The by-product 1 was a substantially non-reducing saccharide with a mass number of 810. Considering the mass number and the fact that the constituent saccharides were only D-glucose molecules, the by-product 1 was estimated to be composed of five D-glucose molecules. When treated with  $\alpha$ -glucosidase, cyclotetrasaccharide and an equimolar of glucose were formed. Upon methylation analysis, 2,3-dimethylated compound, 2,3,4-trimethylated compound, 2,4,6-trimethylated compound, and 2,3,4,6-tetramethylated compound were detected in a molar ratio of 0.83:1.02:1.69:1, meaning a composition ratio of 1:1:2:1. The by-product 1 had a specific rotation of  $[\alpha]^{25}_{\text{D}} +246^\circ$  and a  $^{13}\text{C}$ -NMR spectrum in FIG. 4. The data on the signal assignment of the by-product 1 is in Table 4 below together with those of cyclotetrasaccharide and other saccharides in Experiments 3-4 and 4-3.

**[0100]** Based on these results, the by-product 1 was identified with a blanched cyclotetrasaccharide having a structure represented by Chemical Formula 1.


## Chemical Formula 1:



[0101] The by-product 2 was a substantially non-reducing saccharide with a mass number of 972. Considering the mass number and the fact that the constituent saccharides were D-glucose molecules, the by-product 2 was estimated to be composed of six D-glucose molecules. Upon methylation analysis, 2,4-dimethylated compound, 2,3,4-trimethylated compound, 2,4,6-trimethylated compound, and 2,3,4,6-tetramethylated compound were detected in a molar ratio of 0.94:2.01:1.72:1, meaning a composition ratio of 1:2:2:1. By-product 2 had a specific rotation of  $[\alpha]^{25}_D +246^\circ$  and a  $^{13}\text{C}$ -NMR spectrum in FIG. 5. The data on the signal assignment of the by-product 2 is in Table 4 below together with those of cyclotetrasaccharide and other saccharides in Experiments 3-4 and 4-3.

[0102] Based on these results, the by-product 2 was identified with a blanché cyclotetrasaccharide having a structure represented by Chemical Formula 3.


## Chemical Formula 3:



[0103] The by-product 3 was a substantially non-reducing saccharide with a mass number of 1,296. Considering the mass number and the fact that the constituent saccharides were D-glucose molecules, the by-product 3 was estimated to be composed of eight D-glucose molecules and had a  $^{13}\text{C}$ -NMR spectrum in FIG. 6. The data on the signal assignment of the by-product 3 is in Table 4 below together with those of cyclotetrasaccharide and other saccharides in Experiments 3-4 and 4-3.

[0104] Based on these results, the by-product 3 was identified with a blanché cyclotetrasaccharide having a structure represented by Chemical Formula 4.

## Chemical Formula 4:




[0105] The by-product 4 was a substantially non-reducing saccharide with a mass number of 1,134. Considering the mass number and the fact that the constituent saccharides were D-glucose molecules, the by-product 4 was estimated to be composed of seven D-glucose molecules. Upon methylation analysis, 2,3-dimethylated compound, 2,4-dimethylated compound, 2,3,4-trimethylated compound, 2,4,6-trimethylated compound, and 2,3,4,6-tetramethylated

compound were detected in molar ratio of 0.78:0.78:1.47:1.60:2, meaning a composition ratio of 1:1:1:2:2. The by-product 4 gave a  $^{13}\text{C}$ -NMR spectrum in FIG. 7. The data on the signal assignment of the by-product 3 is in Table 4 below together with those of cyclotetrasaccharide and other saccharides in Experiments 3-4 and 4-3.

[0106] Based on these results, the by-product 4 was identified with a branched cyclotetrasaccharide having a structure represented by Chemical Formula 5.

#### Chemical Formula 5:



[0107] Judging totally the constituent saccharides and the binding fashions of branched parts of branched cyclotetrasaccharides identified in Experiment 3-4, the branched cyclotetrasaccharides as by-products, which were formed in the enzymatic reaction in Experiment 3-1, would have the following characteristics. The branched cyclotetrasaccharides have a basic structure represented by Formula 1, where one or more of  $R_1$  to  $R_{12}$  are optionally substituted  $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)—{ $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 3)- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)—} $_n$   $\alpha$ -D-glucopyranosyl groups, with the proviso that "n" is an integer of at least 0 and, when at least two of the groups of  $R_1$  to  $R_{12}$  are the above groups, the number of each "n" is independent in each group; and in relatively many cases,  $R_2$  and/or  $R_8$  are/is optionally substituted  $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)—{ $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 3)- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)—} $_n$   $\alpha$ -D-glucopyranosyl groups, with the proviso that "n" is an integer of at least 0 and, when both  $R_2$  and  $R_8$  are the above groups, the number of each "n" is independent in each group.

#### Experiment 4: Glycosyl transfer to cyclotetrasaccharide by isolated enzyme

##### Experiment 4-1: Glycosyl transfer by $\alpha$ -isomaltosylglucosaccharide-forming enzyme

[0108] A 10 mM sodium acetate buffer (pH6.0) containing 20% (w/w) of cyclotetrasaccharide, obtained by the method in Experiment 3-2, and 10% (w/w) of maltopentaose, produced by Hayashibara Biochemical Laboratories Inc., Okayama, Japan, was incubated at 30°C for 24 hours after admixed with 3 units/g maltopentaose of a purified  $\alpha$ -isomaltosylglucosaccharide-forming enzyme obtained by the method in Experiment 2-3. The reaction mixture was then boiled for 20 minutes to inactivate the remaining enzyme.

[0109] The resulting mixture was adjusted to pH 5.0 and incubated at 50°C for one hour after admixed with 500 units/g solids of "GLUCOTEAM™", a glucoamylase commercialized by Nagase Biochemicals, Ltd., Kyoto, Japan. Thereafter, the reaction mixture was boiled for 10 minutes to inactivate the remaining enzyme.

[0110] After glucoamylase treatment, the resulting reaction mixture was filtered in a conventional manner with a membrane, desalted, and analyzed on HPLC as in Experiment 3-1. Comparison of retention times on HPLC for the branched cyclotetrasaccharides, which had been isolated and identified in Experiments 3-3 and 3-4, revealed that the reaction mixture contained a branched cyclotetrasaccharide, represented by Chemical Formula 1, in an amount of 17.3% to the total sugars, when calculated based on a relative ratio of its peak area on HPLC. This result indicates that the branched cyclotetrasaccharide of the present invention can be efficiently produced by contacting  $\alpha$ -isomaltosylglucosaccharide-forming enzyme with cyclotetrasaccharide.

##### Experiment 4-2: Glycosyl transfer by $\alpha$ -isomaltosyl-transferring enzyme

[0111] A 10 mM sodium acetate buffer (pH6.0) containing 20% (w/w) cyclotetrasaccharide obtained by the method in Experiment 3-2 and 10% (w/w) of panose produced by Hayashibara Biochemical Laboratories Inc., Okayama, Japan, was incubated at 30°C for 24 hours after admixed with 30 units/g panose of a purified  $\alpha$ -isomaltosyl-transferring enzyme obtained by the method in Experiment 2-2. The reaction mixture was boiled for 20 minutes to inactivate the remaining enzyme.

[0112] The reaction mixture was in a conventional manner filtered with a membrane, desalted, and analyzed on HPLC as shown in Experiment 3-1. Comparison of retention times on HPLC of the branched cyclotetrasaccharides,

which had been isolated and identified in Experiments 3-3 and 3-4, revealed that the reaction mixture contained a branched cyclotetrasaccharide, represented by Chemical Formula 3, in an amount of 4.9% to the total sugars, when calculated based on a relative ratio of its peak area on HPLC. This result revealed that the branched cyclotetrasaccharide of the present invention can be efficiently produced by contacting  $\alpha$ -isomaltosyl-transferring enzyme with cyclotetrasaccharide.

#### Experiment 4-3: Glycosyl transfer by cyclomaltodextrin glucanotransferase (CGTase)

##### Experiment 4-3(a): Enzymatic reaction

[0113] Ten grams of cyclotetrasaccharide obtained by the method in Experiment 3-2 and 10 g of  $\alpha$ -cyclodextrin, produced by Hayashibara Biochemical Laboratories Inc., Okayama, Japan, were dissolved in 30 g of 50 mM sodium acetate buffer (pH 5.5), and then incubated at 50°C for 24 hours after admixed with 10 units/g  $\alpha$ -cyclodextrin of CGTase from *Bacillus stearothermophilus*, commercialized by Hayashibara Biochemical Laboratories Inc., Okayama, Japan. The reaction mixture was boiled for 20 minutes to inactivate the remaining enzyme.

[0114] To the reaction mixture was added 350 g of 50 mM sodium acetate buffer (pH 4.5) and then incubated at 40°C for four hours after admixed with 2,000 units of "GLUCOTEAM™", a glucoamylase commercialized by Nagase Biochemicals, Ltd., Kyoto, Japan. Thereafter, the resulting culture was boiled for 20 minutes to inactivate the remaining enzyme.

[0115] The above reaction mixtures, obtained after the CGTase treatment and the combination treatment with CGTase and glucoamylase, were subjected to HPLC as in Experiment 3-1. While, under the same conditions as above, cyclotetrasaccharide and glucose were analyzed. Based on these, the components in the above reaction mixtures were identified. The results on the reaction mixtures after the CGTase treatment and the combination treatment with CGTase and glucoamylase are respectively shown in FIG. 8a and FIG. 8b.

[0116] A peak X with a retention time of about 10 min, commonly observed in FIGs. 8a and 8b, is a peak for cyclotetrasaccharide, and a peak G with a retention time of about six minutes, specifically observed in FIG. 8b, is a peak for glucose. As shown in FIGs. 8a and 8b, the reaction mixture with the CGTase treatment contained newly formed components with longer retention times than that of cyclotetrasaccharide (FIG. 8a), while that with the combination treatment of CGTase and glucoamylase has almost lost these components except for two components with peaks 1 and 2 (FIG. 8b). These results indicate that the peaks, observed in FIG. 8a, except for that for cyclotetrasaccharide were for glycosyl derivatives of cyclotetrasaccharide to which one or more glycosyl groups were bound. In FIG. 8b, the two peaks, i. e., peaks 1 and 2, with retention times longer than that of cyclotetrasaccharide are glucosyl derivatives of cyclotetrasaccharide where a glycosyl group is bound to a specific position of cyclotetrasaccharide. The retention times of these two components in the reaction mixture, received with the combination treatment of CGTase and glucoamylase, are shown in Table 3 together with respective names and relative values of peak areas.

Table 3

Retention time on HPLC (min*)	Name	Peak area**
18.7	CGTase product 1	About 35%
38.7	CGTase product 2	About 22%

\* Each time determined is a rough value.

\*\* Each value is a relative value when the sum of detected peak areas is regarded as 100.

##### Experiment 4-3(b): Isolation and identification of reaction product

[0117] A reaction mixture, obtained after the combination treatment of CGTase and glucoamylase in the method in Experiment 4-3(a), was filtered with a membrane, and the filtrate was desalted with "DIAION PK218™", a cation exchange resin commercialized by Mitsubishi Chemical Industries, Ltd., Tokyo, Japan; and "AMBERLITE IRA411™", an anion exchange resin commercialized by Japan Organo Co., Ltd., Tokyo, Japan, followed by concentrating. The concentrate was fractionated according to the chromatographic conditions in Experiment 3-2, and the resulting each fraction was analyzed on HPLC in Experiment 3-1 to obtain a fraction containing product 1 or 2 produced by CGTase (called "CGTase product 1 or 2") with a purity of 97%.

[0118] The fraction rich in the CGTase product 1 was in a conventional manner subjected to <sup>13</sup>C-NMR, and the obtained spectrum coincided with that of the by-product 1 of Chemical Formula 1 (FIG. 4) in Experiment 3-4. Based on the result, the CGTase product 1 was identified with a branched cyclotetrasaccharide represented by Chemical formula 1.

[0119] The fraction rich in the CGTase product 2 was analyzed in accordance with the 7th analytical item in Experiment 3-4. The CGTase product 2 was a substantially non-reducing saccharide with a mass number of 972. Considering the mass number and the fact that the constituent saccharides were D-glucose molecules, the CGTase product 2 was judged to be composed of six molecules of D-glucose. When treated with  $\alpha$ -glucosidase, the CGTase product 2 was hydrolyzed into cyclotetrasaccharide and glucose in a molecule ratio of 1:2. Upon methylation analysis, 2,3-dimethylated compound, 2,4,6-trimethylated compound, and 2,3,4,6-tetramethylated compound were observed in a molar ratio of 0.89:1:1.24, meaning a composition ratio of 1:1:1. The CGTase product 2 had a specific rotation of  $[\alpha]^{25}_D +241^\circ$  and gave a  $^{13}\text{C}$ -NMR spectrum in FIG. 9. The assignment of signals of the spectrum are in Table 4 below together with the those of cyclotetrasaccharide and other saccharides described in Experiments 3-4.

Table 4


Carbon number	Chemical shift (ppm)					
	A	B	C	D	E	F
1a	99.34	99.24	99.46	99.40	99.44	99.49
2a	74.28	75.49	72.84	72.87	72.80	75.72
3a	75.45	75.75	82.47	82.98	82.45	75.98
4a	73.35	81.18	73.81	73.72	73.76	81.38
5a	72.78	71.14	72.45	72.46	72.38	71.34
6a	70.22	70.27	70.17	70.10	69.98	70.47
1b	101.20	101.18	101.17	101.08	101.13	101.43
2b	72.64	72.71	72.64	72.63	72.58	72.91
3b	77.31	77.58	77.23	77.13	77.26	77.93
4b	73.62	73.58	73.62	73.65	73.52	73.76
5b	74.23	74.22	74.25	74.28	74.20	74.42
6b	62.88	62.87	62.88	62.87	62.84	63.08
1c	-	99.35	99.32	99.28	99.18	-
2c	-	74.22	74.25	74.28	75.47	-
3c	-	75.49	75.45	75.43	75.77	-
4c	-	73.34	73.36	73.37	81.14	-
5c	-	72.71	72.78	72.75	71.09	-
6c	-	70.15	70.08	70.00	70.20	-
1d	-	101.18	101.17	101.08	101.13	-
2d	-	72.65	72.64	72.63	72.66	-
3d	-	77.37	77.23	77.04	77.51	-
4d	-	73.58	73.57	73.58	73.52	-
5d	-	74.22	74.25	74.28	74.20	-
6d	-	62.87	62.88	62.87	62.84	-
1e	-	102.14	100.59	100.50	100.54	102.34
2e	-	74.40	74.25	74.28	74.20	74.60
3e	-	75.62	75.82	75.85	75.77	75.81
4e	-	72.23	72.16	72.02	72.12	72.43
5e	-	74.10	73.10	73.08	73.05	74.33
6e	-	63.38	68.18	67.85	68.14	63.58
1f	-	-	101.84	102.17	101.79	-
2f	-	-	74.25	72.63	74.20	-
3f	-	-	75.82	82.98	75.77	-
4f	-	-	72.25	72.87	72.20	-
5f	-	-	74.50	74.28	74.45	-
6f	-	-	63.18	62.87	63.13	-

Table 4 (continued)

Carbon number	Chemical shift (ppm)					
	A	B	C	D	E	F
1g	-	-	-	100.50	102.11	-
2g	-	-	-	74.28	74.36	-
3g	-	-	-	75.85	75.57	-
4g	-	-	-	72.24	72.20	-
5g	-	-	-	72.99	74.06	-
6g	-	-	-	67.85	63.33	-
1h	-	-	-	102.17	-	-
2h	-	-	-	74.28	-	-
3h	-	-	-	75.92	-	-
4h	-	-	-	72.24	-	-
5h	-	-	-	74.51	-	-
6h	-	-	-	63.16	-	-
A : Cyclotetrasaccharide, B : By-product 1*, C : By-product 2*, D : By-product 3*, E : By-product 4*, F : CGTase 2* * : By-products 1 to 4 mean those which were isolated in Experiment 3-3 , and CGTase 2 means the CGTase product 2 which was isolated in Experiment 4-3(b).						

[0120] Based on these results, the CGTase product 2 was identified with a branched cyclotetrasaccharide having a structure represented by Chemical formula 2.

#### Chemical Formula 2:



[0121] Totally judging from the constituent saccharides and the binding fashions of the branched part of the branched cyclotetrasaccharide identified in Experiment 4-3(b) and from the results of HPLC analysis on the branched cyclotetrasaccharide after the enzymatic reaction in Experiment 4-3(a), it is considered that the branched cyclotetrasaccharide formed by the enzymatic reaction in Experiment 4-3(a) has the following characteristics: The branched cyclotetrasaccharide has a basic structure represented by Formula 1, wherein in Formula 1 one or more of  $R_1$  to  $R_{12}$ , particularly,  $R_1$  and/or  $R_7$  in relatively many cases are/is an optionally substituted  $\{\alpha\text{-D-glucopyranosyl}-(1\rightarrow 4)\}_n\alpha\text{-D-glucopyranosyl}$  group(s), with the proviso that "n" is an integer of 0 or more, and when at least two of  $R_1$  to  $R_{12}$  are the above groups, "n" is each independent in each group.

#### Experiment 4-4: Glycosyl transfer by $\beta$ -galactosidase from *Bacillus circulans*

##### Experiment 4-4(a): Enzymatic reaction

[0122] Twenty grams of cyclotetrasaccharide obtained by the method in Experiment 3-2 and 20 g of a special grade lactose, commercialized by Wako Pure Chemical Industries, Ltd., Tokyo, Japan, were dissolved in 93.3 g of 20 mM sodium acetate buffer (pH 6.0). The solution was subjected to an enzymatic reaction at 40°C for 24 hours after admixed with 3 units/g lactose of "BIOLACTAN 5™", a  $\beta$ -galactosidase from a microorganism of the species *Bacillus circulans*.

commercialized by Daiwa Kasei K.K., Osaka, Japan, followed by boiling the resulting mixture for 20 minutes to inactivate the remaining enzyme.

[0123] The reaction mixture thus obtained and an aqueous solution of cyclotetrasaccharide were analyzed on HPLC in Experiment 3-1. As a result, the HPLC analysis revealed the formation of at least three kinds of new components, which had different retention times from that of cyclotetrasaccharide (about 10 minutes), in the reaction mixture. Table 5 shows the retention times of the three components together with their names and relative values of peak areas.

Table 5

Retention time on HPLC (min*)	Name	Peak area**
14.0	$\beta$ -Galactosidase product 1	12.2%
19.7	$\beta$ -Galactosidase product 2	2.9%
20.3	$\beta$ -Galactosidase product 3	1.1%

\* Each time determined is a rough value.

\*\* Each value is a relative value when the sum of detected peak areas is regarded as 100.


#### Experiment 4-4(b): Isolation and identification of reaction product

[0124] To a reaction mixture obtained by the method in Experiment 4-4(a) was added 4.8 g of sodium hydroxide and kept at 100°C for one hour to decompose reducing saccharides. The resulting mixture was decolorized, desalted, filtered, and concentrated in a conventional manner, followed by subjecting the concentrate to a preparative liquid chromatography using "YMN-PACK ODS-AQR355-15AQ, S-10/20 $\mu$ m, 120A™", a preparative column commercialized by YMC Co., Ltd., Tokyo, Japan, and using a purified, deionized water as a moving bed. The eluate was analyzed on HPLC as described in Experiment 3-1, resulting in obtaining a fraction containing a product produced by  $\beta$ -galactosidase (or  $\beta$ -galactosidase product 1) with a purity of at least 97%.

[0125] The above fraction was analyzed in accordance with seven analytical items in Experiment 3-4. The  $\beta$ -galactosidase product 1 was a substantially non-reducing saccharide with a mass number of 810. The constituent saccharides of the  $\beta$ -galactosidase product 1 were D-glucose and D-galactose which were present in a composition ratio of 4:1. Judging from its mass number, the  $\beta$ -galactosidase product 1 was considered to be composed of four molecules of D-glucose and one molecule of D-galactose. The  $\beta$ -galactosidase product 1 had a specific rotation of  $[\alpha]^{25}_D +200^\circ$  and a  $^{13}\text{C}$ -NMR spectrum of FIG. 10. Table 7 shows the results of assignment of signals of the spectrum together with those of cyclotetrasaccharide and other results in Experiments 4-5 to 4-7.

[0126] Based on these results, the  $\beta$ -galactosidase product 1 was identified with a branched cyclotetrasaccharide represented by Chemical Formula 6.

#### Chemical Formula 6:



#### Experiment 4-5: Glycosyl transfer by $\beta$ -galactosidase from *Aspergillus niger*

##### Experiment 4-5 (a): Enzymatic reaction

[0127] Twenty grams of cyclotetrasaccharide obtained by the method in Experiment 3-2 and 20 g of a special grade lactose, commercialized by Wako Pure Chemical Industries, Ltd., Tokyo, Japan, were dissolved in 93.3 g of 20 mM sodium acetate buffer (pH 4.5), and then incubated at 40°C for 24 hours after admixed with 10 units/g lactose of "LACTASE YA-OTM", a  $\beta$ -galactosidase from a microorganism of the species *Aspergillus niger*, commercialized by Yakult Pharmaceutical Inc. Co., Ltd., Tokyo, Japan. Thereafter, the resulting reaction mixture was boiled for 20 min to inactivate the remaining enzyme.

**[0128]** The reaction mixture thus obtained and an aqueous solution of cyclotetrasaccharide were analyzed on HPLC described in Experiment 3-1. As a result, the HPLC analysis revealed the formation of at least three kinds of new components, which had different retention times from that of cyclotetrasaccharide (about 10 minutes), in the reaction mixture. Table 7 shows the retention times of the three components together with their names and relative values of peak areas.

Table 6

Retention time on HPLC (min*)	Name	Peak area**
14.1	Chemical Formula 6***	3.3%
15.1	$\beta$ -Galactosidase product 4	0.7%
19.1	$\beta$ -Galactosidase product 5	7.1%

\* Each value determined is a rough value.

\*\* Each value is a relative value when the sum of detected peak areas is regarded as 100.

\*\*\* Based on its retention time, it was identified with a branched cyclotetrasaccharide, represented by Chemical Formula 6 in Experiment 4-4(b).


## Experiment 4-5(b): Isolation and identification of reaction product

**[0129]** To the reaction mixture, obtained by the method in Experiment 4-5(a), was added 4.8 g of sodium hydroxide and kept at 100°C for one hour to decompose reducing saccharides. The resulting mixture was decolorized, desalted, filtered, and concentrated in a conventional manner. The concentrate was subjected to preparative liquid chromatography using "YMN-PACK ODS-AQR355-15AQ, S-10/20 μm, 120A", a preparative column commercialized by YMC Co., Ltd., Tokyo, Japan, and using a purified, deionized water as a moving bed. The eluate was analyzed on HPLC described in Experiment 3-1, resulting in obtaining a fraction containing a product formed by β-galactosidase (or β-galactosidase product 4) with a purity of at least 94%, and another fraction containing a product formed by β-galactosidase (or β-galactosidase product 5) with a purity of at least 99%.

**[0130]** The above fraction of  $\beta$ -galactosidase product 4 was analyzed in accordance with the seven analytical items in Experiment 3-4. The  $\beta$ -galactosidase product 4 was a substantially non-reducing saccharide with a mass number of 973. The constituent saccharides were D-glucose and D-galactose, which were present in a molar ratio of 2:1. Judging from its mass number, the  $\beta$ -galactosidase product 4 was considered to be composed of four molecules of D-glucose and two molecules of D-galactose. Upon methylation analysis, 2,4-dimethylated glucose, 2,3,4-trimethylated glucose, 2,4,6-trimethylated glucose, 2,3,4-trimethylated galactose, and 2,3,4,6-tetramethylated galactose were detected in a molar ratio of 1:1.86:0.96:1.34:1.12, meaning a composition ratio of 1: 2 :1:1:1. Upon  $^{13}\text{C}$ -NMR, the  $\beta$ -galactosidase product 4 gave a spectrum of FIG. 11. Table 7 shows the assignment of signals of the spectrum together with those of cyclotetrasaccharide and other results in Experiments 4-5 to 4-7.

**[0131]** Based on these results, the  $\beta$ -galactosidase product 4 was identified with a branched cyclotetrasaccharide represented by Chemical Formula 8.


Chemical Formula 8:



**[0132]** The above fraction rich in the  $\beta$ -galactosidase product 5 was analyzed in accordance with the seven analytical items in Experiment 3-4. The  $\beta$ -galactosidase product 5 was a substantially non-reducing saccharide with a mass number of 810. The constituent saccharides were D-glucose and D-galactose present in a composition ratio of 4:1. Judging from its mass number, the  $\beta$ -galactosidase product 4 was considered to be composed of four molecules of D-glucose and one molecule of D-galactose. Upon methylation analysis, 2,4-dimethylated glucose, 2,3,4-trimethylated glucose, 2,4,6-trimethylated glucose, and 2,3,4,6-tetramethylated galactose were detected in a molar ratio of 1:2.02:1.00:1.04, meaning a composition ratio of 1: 2: 1: 1. Upon  $^{13}\text{C}$ -NMR, the  $\beta$ -galactosidase product 5 gave a spectrum







#### Experiment 4-7(a):-Enzymatic reaction

**[0140]** Twenty grams of cyclotetrasaccharide obtained by the method in Experiment 3-2 and 10 g of "NA-COS-Y<sup>TM</sup>", a chichin oligosaccharide commercialized by Yaizu Suisankagaku Industry Co., Ltd., Shizuoka, Japan, containing about 55%, d.s.b., of a chitin oligosaccharide with a polymerization degree of two to six, were dissolved in 45 g of 50 mM sodium acetate buffer (pH 4.5), and then incubated at 60°C for nine days after admixed with 2.8 g of albumin lysozyme, commercialized by Seikagaku Corporation, Tokyo, Japan. Thereafter, the reaction mixture was boiled for 20 min to inactivate the remaining enzyme.

**[0141]** As a treatment before HPLC, the resulting reaction mixture was centrifuged, then the supernatant was filtered by using "SEP-0013™", an ultrafiltration membrane commercialized by Asahi Kasei Corporation, Tokyo, Japan, to remove proteins and desalted in a conventional manner. The pretreated solution and an aqueous solution of cyclotetrasaccharide were subjected to HPLC described in Experiment 3-1. As a result, the HPLC analysis revealed the formation of at least one newly formed component with a retention time of 36.6 min, which differed from cyclotetrasaccharide with a retention time of about 10 min. Upon the HPLC analysis, the newly-formed component had a peak area of about 7.3% to the total peak areas.

## Experiment 4-7(b): Isolation and identification of reactive product

**[0142]** A reaction mixture, obtained by the method in Experiment 4-7(a), was similarly treated as the pretreatment of HPLC in Experiment 4-7(a), and then subjected to preparative liquid chromatography according to the method in Experiment 4-5(b), and to HPLC analysis described in Experiment 3-1, followed by collecting a fraction containing a product formed by lysozyme (or a lysozyme product), with a purity of at least 99%, after analysis and confirmation on the HPLC analysis in Experiment 3-1.

**[0143]** The above fraction rich in the lysozyme product was analyzed according to the seven analytical items in Experiment 3-4. The lysozyme product was a substantially non-reducing saccharide with a mass number of 851. The lysozyme product had D-glucose and N-acetyl-D-glucosamine (N-acetyl-D-chitosamine) as constituent saccharides in a composition ratio of 4:1. Judging from its mass number, the lysozyme product was considered to be composed of four molecules of D-glucose and one molecule of N-acetyl-D-glucosamine. Upon methylation analysis, 2,4-dimethylated glucose, 2,3,4-trimethylated glucose, and 2,4,6-trimethylated glucose were observed in a molar ratio of 1.02 : 1.67, meaning a composition ratio of 1:1:2. The product had a specific rotation of  $[\alpha]^{25}_D +246^\circ$  and a  $^{13}\text{C}$ -NMR spectrum of FIG. 14. Table 7 shows the assignment of signals of the product together with that of cyclotetrasaccharide and other results described in Experiments 4-4 to 4-6.

Table 7

Carbon number	Chemical shift (ppm)					
	A	$\beta$ -Ga11*	$\beta$ -Ga14*	$\beta$ -Ga15*	$\alpha$ -Ga1*	Lys*
1a	99.34	98.96	99.39	99.36	99.25	99.47
2a	74.28	73.67	74.27	74.24	74.28	72.48

A : Cyclotetrasaccharide

\*:  $\beta$ -Gal means  $\beta$ -galactosidase product 1 isolated in Experiment 4-4(b),  $\beta$ -Gal4 and  $\beta$ -Gal5 mean  $\beta$ -galactosidase products 4 and 5 isolated in Experiment 4-5(b),  $\alpha$ -Gal means  $\alpha$ -galactosidase product isolated in Experiment 4-6(b), and Lys means lysozyme product isolated in Experiment 4-7(b).


Table 7 (continued)

Carbon number	Chemical shift (ppm)					
	A	$\beta$ -Ga11*	$\beta$ -Ga14*	$\beta$ -Ga15*	$\alpha$ -Ga1*	Lys*
3a	75.45	83.59	75.45	75.42	75.44	84.53
4a	73.35	73.11	73.28	73.24	73.42	74.03
5a	72.78	72.44	72.76	72.76	72.60	72.57
6a	70.22	70.06	70.38	70.35	70.10	70.18
1b	101.20	101.04	101.22	101.27	101.07	101.13
2b	72.64	72.60	72.65	72.62	72.60	72.69
3b	77.31	77.29	77.37	77.36	77.35	77.22
4b	73.62	73.62	73.34	73.31	73.61	73.65
5b	74.23	74.21	73.46	73.45	72.79	74.23
6b	62.88	62.86	70.66	70.59	67.94	62.84
1c	-	99.21	99.39	99.36	99.25	99.31
2c	-	74.26	74.27	74.24	74.28	74.28
3c	-	75.41	75.45	75.42	75.44	75.44
4c	-	73.34	73.22	73.24	73.35	73.35
5c	-	72.70	72.76	72.73	72.60	72.77
6c	-	70.06	70.22	70.20	70.10	70.18
1d	-	100.95	101.22	101.21	100.96	101.13
2d	-	72.54	72.57	72.54	72.60	72.63
3d	-	77.03	77.24	77.21	77.18	77.22
4d	-	73.53	73.34	73.31	73.61	73.60
5d	-	74.21	74.27	74.24	74.22	74.23
6d	-	62.86	62.88	62.86	62.87	62.84
1e	-	107.57	105.93	106.01	100.55	-
2e	-	74.08	73.42	73.58	71.20	-
3e	-	75.18	75.26	75.42	72.29	-
4e	-	71.46	71.37	71.34	71.97	-
5e	-	78.02	76.57	77.83	73.75	-
6e	-	64.18	71.60	63.70	63.87	-
1f	-	-	106.02	-	-	104.66
2f	-	-	73.62	-	-	58.43
3f	-	-	75.45	-	-	76.38
4f	-	-	71.31	-	-	71.86
5f	-	-	77.87	-	-	78.52
6f	-	-	63.67	-	-	63.38
CO	-	-	-	-	-	177.58
CH <sub>3</sub>	-	-	-	-	-	24.92

A : Cyclotetrasaccharide

\* :  $\beta$ -Gal1 means  $\beta$ -galactosidase product 1 isolated in Experiment 4-4(b),  $\beta$ -Gal4 and  $\beta$ -Gal5 mean  $\beta$ -galactosidase products 4 and 5 isolated in Experiment 4-5(b),  $\alpha$ -Gal means  $\alpha$ -galactosidase product isolated in Experiment 4-6(b), and Lys means lysozyme product isolated in Experiment 4-7(b).

[0144] Based on these results, the lysozyme product obtained in this Experiment was identified with a branched cyclotetrasaccharide represented by Chemical Formula 10.



**[0148]** The data on X-ray diffraction analysis of all the above crystals are in FIGs. 15 to 19. Predominant diffraction angles ( $2\theta$ ) observed in the analysis are tabulated in Table 8 along with the results on color, moisture content, and melting point.

Table 8

Compound	Main diffraction angles ( $2\theta$ )	Color	Moisture content	Number* of crystal of water	Melting point
Chemical Formula 1	8.1°, 12.2° 14.2°, 15.4°	White	11.1%	5 to 6	Not measurable, as it was decomposed at around 270°C.
Chemical Formula 2	5.6°, 8.8° 16.9°, 21.9°	White	17.5%	11 to 12	Not measurable, as it was decomposed at around 280°C.
Chemical Formula 3	7.9°, 12.1° 17.9°, 20.2°	White	15.8%	10 to 11	Not measurable, as it was decomposed at around 275°C.
Chemical Formula 6	11.0°, 12.3° 12.8°, 24.9°	White	17.1%	9 to 10	93°C
Chemical Formula 7	8.7°, 13.0° 21.7°, 26.1°	White	11.0%	5 to 6	Not measurable, as it was decomposed at around 245°C.

\*: It was determined based on the water content measured.

[0149] The results of thermal properties of all the above crystals are respectively shown in FIG. 20 to 24. As shown in FIG. 20, the compound of Chemical Formula 1 gave a weight reduction corresponding to that of four moles of water as the temperature increased to 150°C, and gave a weight reduction due to its decomposition at a temperature of around 300°C or over. These results indicate that the compound of Chemical Formula 1 in the form of a penta- or hexa-hydrous crystal is converted into a mono- or di-hydrous crystal when heated to 150°C under normal pressure.

[0150] As shown in FIG. 21, the compound of Chemical Formula 2 gave a weight reduction corresponding to that of six to seven moles of water as the temperature increased to about 150°C, and also gave a weight reduction due to its decomposition at a temperature of around 300°C or over. These results indicate that the compound of Chemical Formula 2 in the form of a undeca- or dodeca-hydrous crystal is converted into a tetra- or penta-hydrous crystal when heated to 150°C under normal pressure.

[0151] As shown in FIG. 22, the compound of Chemical Formula 3 gave a weight reduction corresponding to that of six to seven moles of water as the temperature increased to about 110°C, and also gave a weight reduction due to its decomposition at a temperature of around 300°C or over. These results indicated that the compound of Chemical Formula 3 in the form of a deca- or undeca-hydrous crystal is converted into a tri- or tetra-hydrous crystal when heated to 114°C under normal pressure.

[0152] As shown in FIG. 23, the compound of Chemical Formula 6 gave a weight reduction corresponding to that of seven to eight moles of water as the temperature increased to about 120°C, and also gave a weight reduction due to its decomposition at a temperature of around 300°C or over. These results indicate that the compound of Chemical Formula 6 in the form of a nona- or deca-hydrous crystal is converted into a mono- or di-hydrous crystal when heated to 120°C under normal pressure.

[0153] As shown in FIG. 24, the compound of Chemical Formula 7 gave a weight reduction corresponding to that of five to six moles of water as the temperature increased to about 130°C, and also gave a weight reduction due to its decomposition at a temperature of around 300°C or over. These results indicate that the compound of Chemical Formula 7 in the form of a penta- or hexa-hydrous crystal is converted into an anhydrous or monohydrous crystal when heated to 130°C under normal pressure.

#### Example A-1: Syrup containing branched cyclotetrasaccharide represented by Chemical Formulae 1 and 2

[0154] One part by weight of cyclotetrasaccharide obtained by the method in Experiment 3-2 and one part by weight of  $\alpha$ -cyclodextrin, commercialized by Hayashibara Biochemical Laboratories Inc., Okayama, Japan, were dissolved in three parts by weight of 50 mM sodium acetate buffer (pH 5.5). The resulting solution was incubated at 50°C for 24 hours after admixed with 10 units/g  $\alpha$ -cyclodextrin of CGTase from a microorganism of the species *Bacillus stearothermophilus*, commercialized by Hayashibara Biochemical Laboratories Inc., Okayama, Japan, and the reaction mixture was boiled for 20 minutes to inactivate the remaining enzyme.

[0155] To the reaction mixture was added 350 g of 50 mM sodium acetate buffer (pH 4.5) and then incubated at 40°C for four hours after admixed with 200 units of "GLUCOTEAM™", a glucoamylase specimen commercialized by Nagase Biochemicals, Ltd., Kyoto, Japan, per gram of the initially added  $\alpha$ -cyclodextrin. Thereafter, the resulting mixture was boiled for 20 min to inactivate the remaining enzyme.

[0156] The reaction mixture thus obtained was membrane filtered, desalted with "DIAION PK218™", a cation exchange resin commercialized by Mitsubishi Chemical Industries, Ltd., Tokyo, Japan, and "AMBERLITE IRA411™", an anion exchange resin commercialized by Japan Organo Co., Ltd., Tokyo, Japan, and concentrated. The concentrate was fractionated by chromatography according to the conditions used in Experiment 3-2, and the resulting each fraction was analyzed on the HPLC in Experiment 3-1 to collect a fraction containing a branched cyclotetrasaccharide, represented by Chemical Formulae 1 and 2, with a purity of 85% or higher each. The fraction was concentrated into a syrup with a solid concentration of about 50% (w/w).

[0157] The syrup can be advantageously used as a material for products in a variety fields of foods, beverages, cosmetics, and pharmaceuticals without any treatment or after concentrated, dried, crystallized, or pulverized into a product in the form of an amorphous powder, molasses, block, etc.

#### Example A-2: Syrup containing branched cyclotetrasaccharide represented by Chemical Formula 3

[0158] Two parts by weight of cyclotetrasaccharide obtained by the method in Experiment 3-2 and one part by weight of panose commercialized by Hayashibara Biochemical Laboratories Inc., Okayama, Japan, were dissolved in seven parts by weight of 10 mM sodium acetate buffer (pH 6.0). The resulting solution was incubated at 30°C for 24 hours after admixed with 30 units/g panose of a purified  $\alpha$ -isomaltosyl-transferring enzyme obtained by the method in Experiment 2-2, and the reaction mixture was boiled for 20 min to inactivate the remaining enzyme.

[0159] The reaction mixture thus obtained was membrane filtered, desalted with "DIAION PK218™", a cation exchange resin commercialized by Mitsubishi Chemical Industries, Ltd., Tokyo, Japan, and "AMBERLITE IRA411™", an

anion exchange resin commercialized by Japan Organo Co., Ltd., Tokyo, Japan, and concentrated. The concentrate was fractionated by chromatography according to the conditions in Experiment 3-2, and the resulting each fraction was analyzed on the HPLC in Experiment 3-1 to collect a fraction with a branched cyclotetrasaccharide, represented by Chemical Formula 3, with a purity of 80% or higher. The fraction was concentrated into a syrup with a solid concentration of about 40% (w/w).

[0160] The syrup can be advantageously used as a material for products in a variety fields of foods, beverages, cosmetics, and pharmaceuticals without any treatment or after concentrated, dried, crystallized, or pulverized into a product in the form of an amorphous powder, molasses, block, etc.

#### Example A-3: Syrup containing branched cyclotetrasaccharide represented by Chemical Formula 6

[0161] Two parts by weight of cyclotetrasaccharide obtained by the method in Experiment 3-2 and two parts by weight of lactose were mixed and dissolved in nine parts by weight of 20 mM sodium acetate buffer (pH 6.0). The resulting solution was incubated at 40°C for 24 hours after admixed with three units/g lactose of "BIOLACTAN™", a  $\beta$ -galactosidase specimen from a microorganism of the species *Bacillus circulans* commercialized by Daiwa Kasei K.K., Osaka, Japan, and the reaction mixture was boiled for 20 minutes to inactivate the remaining enzyme.

[0162] To the reaction mixture thus obtained was added 0.5 part by weight of sodium hydroxide and kept at 100°C for one hour to decompose reducing saccharides. The obtained reaction mixture was in a conventional manner de-salted, filtered, and concentrated. The concentrate was subjected to preparative liquid chromatography using "YMC-PACK ODS-AQR355-15AQ S-10/20  $\mu$ m, 120A™", a preparative column commercialized by YMC Co., Ltd., Tokyo, Japan, where a purified, deionized water was used as a moving phase. The eluate was analyzed on the HPLC described in Experiment 3-1 to collect a fraction containing a branched cyclotetrasaccharide, represented by Chemical Formula 6, with a purity of at least 85%. The fraction was concentrated to obtain a syrup with a solid concentration of 40% (w/w).

[0163] The syrup can be advantageously used as a material for products in variety fields of foods, beverages, cosmetics, and pharmaceuticals without any treatment or after concentrated, dried, crystallized, or pulverized into a product in the form of an amorphous powder, molasses, block, etc.

#### Example A-4: Syrup containing branched cyclotetrasaccharide represented by Chemical Formula 7

[0164] Two parts by weight of cyclotetrasaccharide obtained by the method in Experiment 3-2 and two parts by weight of lactose were dissolved in nine parts by weight of 20 mM sodium acetate buffer (pH 4.5). The resulting solution was incubated at 40°C for 24 hours after admixed with 10 units/g lactose of "LACTASE YA-O™", a  $\beta$ -galactosidase specimen from a microorganism of the species *Aspergillus niger* commercialized by Yakult Pharmaceutical Inc. Co., Ltd., Tokyo, Japan, and the reaction mixture was boiled for 20 min to inactivate the remaining enzyme.

[0165] To the reaction mixture thus obtained was added 0.5 part by weight of sodium hydroxide and kept at 100°C for one hour to decompose reducing saccharides. The resulting reaction mixture was in a conventional manner de-salted, filtrated, and concentrated. The concentrate was subjected to preparative liquid chromatography using "YMC-PACK ODS-AQR355-15AQ, S-10/20  $\mu$ m 120A™", a preparative column commercialized by YMC Co., Ltd., Tokyo, Japan, where a purified, deionized water was used as a moving phase. The eluate was analyzed on the HPLC described in Experiment 3-1 to collect a fraction containing a branched cyclotetrasaccharide, represented by Chemical Formula 7, with a purity of at least 85%. The fraction was concentrated into a syrup with a solid concentration of 45% (w/w).

[0166] The syrup can be advantageously used as a material for products in variety fields of foods, beverages, cosmetics, and pharmaceuticals without any treatment or after concentrated, dried, crystallized, or pulverized into a product in the form of an amorphous powder, molasses, block, etc.

#### Example A-5: Crystal of branched cyclotetrasaccharide represented by Chemical Formula 1 or 2

[0167] According to Example A-1, a reaction mixture, obtained through the sequential treatments of CGTase and glucoamylase and the inactivation of enzyme, was subjected to chromatographic separation similarly as in Example A-1. The eluate was analyzed on the HPLC in Experiment 3-1 to collect fractions containing branched cyclotetrasaccharides, represented by Chemical Formulae 1 and 2, with a purity of 97% or higher each. The fractions were respectively concentrated and then admixed with a corresponding crystal of Chemical Formula 1 or 2 obtained in Experiment 5 as a seed crystal to effect sufficient crystallization. The crystals were centrifuged and collected in a conventional manner, and the collected crystals were dried at ambient temperature to obtain respective crystals of branched cyclotetrasaccharides, represented by Chemical Formulae 1 and 2, with a purity of at least 99% each. Measurement of moisture content described in Experiment 5 revealed that the compound of Chemical Formula 1 was a penta- or hexa-



hydrous crystal, while the compound of Chemical Formula 2 was an undeca- or dodeca-hydrous crystal.

[0168] The crystals can be arbitrarily used as materials for products in variety fields of foods, beverages, cosmetics, and pharmaceuticals.

#### 5 Example A-6: Crystal of branched cyclotetrasaccharide represented by Chemical Formula 3

[0169] According to Example A-2, a reaction mixture, obtained through the treatments of  $\beta$ -galactosidase and the inactivation of enzyme, was subjected to chromatographic separation similarly as in Example A-2. The eluate was analyzed on the HPLC described in Experiment 3-1 to collect a fraction containing branched cyclotetrasaccharides, represented by Chemical Formula 3, with a purity of at least 97%. The fraction was concentrated and then admixed with the crystal of the compound of Chemical Formula 3 obtained in Experiment 5 as a seed crystal to effect sufficient crystallization. The formed crystal was centrifuged and collected in a conventional manner, and the collected crystal was dried at ambient temperature to obtain a crystal of a branched cyclotetrasaccharide, represented by Chemical Formula 3, with a purity of at least 99%. Measurement of moisture content described in Experiment 5 revealed that the crystal was a deca- or undeca-hydrous crystal.

[0170] The crystal can be arbitrarily used as a material for products in variety fields of foods, beverages, cosmetics, and pharmaceuticals.

#### 20 Example A-7: Crystal of branched cyclotetrasaccharide represented by Chemical Formula 6

[0171] According to Example A-3, a reaction mixture, obtained through the treatments of  $\alpha$ -isomaltosyl-transferring enzyme and the inactivation of enzyme, was subjected to chromatographic separation similarly as in Example A-3. The eluate was analyzed on the HPLC described in Experiment 3-1 to collect a fraction containing branched cyclotetrasaccharides, represented by Chemical Formula 6, with a purity of at least 96%. The fraction was concentrated and then admixed with the crystal of the compound of Chemical Formula 6 obtained in Experiment 5 as a seed crystal to effect sufficient crystallization. The crystal was centrifuged and collected in a conventional manner, and the collected crystal was dried at ambient temperature to obtain a crystal of a branched cyclotetrasaccharide, represented by Chemical Formula 6, with a purity of at least 99%. Measurement of moisture content described in Experiment 5 revealed that the crystal was a nona- or deca-hydrous crystal.

[0172] The crystal can be arbitrarily used as a material for products in variety fields of foods, beverages, cosmetics, and pharmaceuticals.

#### 30 Example A-8: Crystal of branched cyclotetrasaccharide represented by Chemical Formula 7

[0173] According to Example A-4, a reaction mixture, obtained through the treatments of  $\beta$ -galactosidase and the inactivation of enzyme, was subjected to chromatographic separation similarly as in Example A-4. The eluate was analyzed on the HPLC described in Experiment 3-1 to collect a fraction containing branched cyclotetrasaccharides, represented by Chemical Formula 7, with a purity of at least 97%. The fraction was concentrated and admixed with the crystal of the compound of Chemical Formula 7 obtained in Experiment 5 as a seed crystal to effect sufficient crystallization. The crystal was centrifuged and collected in a conventional manner, and the collected crystal was dried at ambient temperature to obtain a crystal of a branched cyclotetrasaccharide, represented by Chemical Formula 7, with a purity of at least 99%. Measurement of moisture described in Experiment 5 revealed that the crystal was a penta- or hexa-hydrous crystal.

[0174] The crystal can be arbitrarily used as a material for products in variety fields of foods, beverages, cosmetics, and pharmaceuticals.

#### 45 Example A-9: Syrup containing branched cyclotetrasaccharides

[0175] 3.7 kg of "PINE-DEX #100<sup>TM</sup>", a partial starch hydrolyzate commercialized by Matsutani Chemical Ind., Tokyo, Japan, was dissolved in 35 L of 10 mM sodium acetate buffer (pH 6.0), and the solution was incubated at 30°C for two days after admixed with 17,500 units of a cyclotetrasaccharide-forming activity of an enzyme preparation obtained by the method in Experiment 2-1, and the reaction mixture was boiled for 20 minutes to inactivate the remaining enzyme. The reaction mixture was cooled to 45°C and admixed with 11 g (137,500 units) of "NEO-SPITASE<sup>TM</sup>", an  $\alpha$ -amylase specimen commercialized by Nagase Biochemicals, Ltd., Kyoto, Japan, and 44 grams (140,800 units) of "GLU-COZYME<sup>TM</sup>", a glucoamylase specimen commercialized by Nagase Biochemicals, Ltd., Kyoto, Japan, and then adjusted to pH 6.0, followed by enzymatically reacting at 45°C for one day. The reaction mixture thus obtained was boiled for 20 minutes to inactivate remaining enzymes, and then cooled and filtered in a conventional manner to obtain a filtrate. The filtrate was concentrated to give a solid concentration of about 16% (w/w) by using a reverse osmosis

membrane. The concentrate was subjected in a conventional manner to decoloration, desalting, filtration, and concentration to obtain about 6.1 kg of a syrup containing 3.5 kg of solids consisting of 12% of branched cyclotetrasaccharides, 44% of cyclotetrasaccharide, 25% of glucose, and 19% of oligosaccharides.

**[0176]** Since the syrup is substantially free of crystallization and easily produced on an industrial scale and at a lesser cost, it can be arbitrarily used as a material for products in a variety fields of foods, beverages, cosmetics, and pharmaceuticals.

#### Example A-10: Syrup containing branched cyclotetrasaccharides

**[0177]** 6.1 kg of a saccharide solution, obtained by the method in Experiment 3-1, was fed to ten columns, having an inner diameter of 13.5 cm and a length of 160 cm each, which had been packed with about 225 L of "AMBERLITE CR-1310 (Na-form)<sup>TM</sup>", an ion-exchange resin commercialized by Japan Organo Co., Ltd., Tokyo, Japan, and cascaded in series, and chromatographed at a flow rate of about 45 L/h of water and at a column temperature of 60°C. The eluate from the columns was fractionated and determined for saccharide composition by the HPLC described in Experiment 3-1. Fractions, which were relatively rich in cyclotetrasaccharide, were collected and pooled to obtain a saccharide solution with a solid content of about 1,530 g. The saccharide solution, i.e., a high cyclotetrasaccharide content fraction, was analyzed on the HPLC under the same conditions as above, and based on the peak areas determined on the HPLC analysis, it was composed of 79.8% of cyclotetrasaccharide and 6.1% of isomaltose to the total sugars.

**[0178]** The saccharide solution in an amount equal to a solid content of 1,310 g was adjusted to pH 5.0 and 50°C, and then incubated for 20 hours after admixed with 1,000 units/g solids of "TRANSGLUCOSIDASE L AMANO<sup>TM</sup>", an  $\alpha$ -glucosidase specimen commercialized by Amano Pharmaceutical Co., Ltd., Aichi, Japan, and 60 units/g solids of "GLUCOZYMET<sup>TM</sup>", a glucoamylase specimen commercialized by Nagase Biochemicals, Ltd., Kyoto, Japan. After removing insoluble substances by filtration, the above enzymatic reaction mixture was desalted with "DIAION PK218<sup>TM</sup>", a cation exchange resin commercialized by Mitsubishi Chemical Industries, Ltd., Tokyo, Japan, and "AMBERLITE IRA411<sup>TM</sup>", an anion exchange resin commercialized by Japan Organo Co., Ltd., Tokyo, Japan, and then concentrated. The concentrate was fractionated according to the conditions as used in the above chromatographic separation to collect a fraction of cyclotetrasaccharide with a purity of 97%. The fraction was in a conventional manner decolorized, desalted, filtered, and concentrated to obtain a saccharide solution with a solid content of 1,260 g. After adjusted to a solid concentration of about 50% (w/w), the saccharide solution was placed in a cylindrical plastic vessel and cooled from 65°C to 20°C over about 20 hours under gentle stirring conditions. The resulting mixture was subjected to separation, and the obtained mother liquor was purified and concentrated into a syrup with a solid concentration of about 45%, consisting of 4% of branched cyclotetrasaccharides, 94% of cyclotetrasaccharide, 1% of glucose, and 1% of other saccharides.

**[0179]** Since the syrup is substantially free of crystallization and easily produced on an industrial scale and at a lesser cost, it can be arbitrarily used as a material for products in a variety fields of foods, beverages, cosmetics, and pharmaceuticals.

#### Example A-11: Syrup containing branched cyclotetrasaccharides

**[0180]** To 400 g of a syrup containing branched cyclotetrasaccharides obtained in Example A-9 was added 0.1 g/g solids of "N154<sup>TM</sup>" commercialized by Nikki Chemical Co., Ltd., Kanagawa, Japan, an activated Raney nickel catalyst with an alkali. The mixture was placed in an autoclave and hydrogenated by reacting at 100°C for four hours and further at 120°C for two hours while stirring and keeping at a hydrogen pressure of 100 kg/cm<sup>2</sup>. After cooled, the resulting hydrogenated mixture was taken out from the autoclave and filtered by passing through an activated carbon layer with about one centimeter in thickness to remove the Raney nickel catalyst. The filtrate was in a conventional manner decolorized with an activated charcoal, desalted with ion-exchange resins in H- and OH-forms, purified, and concentrated to give a concentration of about 40% and to obtain a syrup which was substantially free of crystallization and composed of 12% of branched cyclotetrasaccharides, 44% of cyclotetrasaccharide, 25% of sorbitol, and 19% of other saccharides.

**[0181]** Since the syrup is substantially free of crystallization and easily produced on an industrial scale and at a lesser cost, it can be arbitrarily used as a material for products in a variety fields of foods, beverages, cosmetics, and pharmaceuticals.

#### Example A-12: Syrup of branched cyclotetrasaccharides

**[0182]** A substantially non-reducing and non-crystallizing syrup, which had a solid concentration of about 55% and consisted of 4% of branched cyclotetrasaccharides, 94% of cyclotetrasaccharide, 1% of sorbitol, and 1% of other saccharides, was obtained similarly as in Example A-11 except for replacing 400 g of the syrup containing branched

cyclotetrasaccharides obtained in Example A-9 with 400g of the syrup containing branched cyclotetrasaccharides obtained in Example A-10.

**[0183]** Since the syrup is substantially free of crystallization and easily produced on an industrial scale and at a lesser cost, it can be arbitrarily used as a material for products in a variety of fields of foods, beverages, cosmetics, and pharmaceuticals.

#### Example B-1: Sweetener

**[0184]** To 0.8 part by weight of a branched cyclotetrasaccharide crystal, penta- or hexa-hydrate, represented by Chemical Formula 1, obtained by the method in Example A-5, were homogeneously added 0.2 part by weight of "TRE-HA™", a crystalline trehalose hydrate commercialized by Hayashibara Shoji Inc., Okayama, Japan, 0.01 part by weight of "αG SWEET™", an α-glycosylstevioside product commercialized by Toyo Sugar Refining Co., Tokyo, Japan, and 0.01 part by weight of "ASPALTAME™", a product of L-aspartyl-L-phenylalanine methyl ester, followed by feeding the resulting mixture to a granulator to obtain a granular sweetener. The product has a satisfactory sweetness and an about two-fold higher sweetening power of sucrose. Since the branched cyclotetrasaccharide is hardly digestible and fermentable and is substantially free from calorie, the product has only about 1/10 calorie of that of sucrose with respect to sweetening power. In addition, the product is substantially free of deterioration and stable even when stored at room temperature. Thus, the product is preferable as a high quality, low caloric, less cariogenic sweetener.

#### Example B-2: Hard candy

**[0185]** One hundred parts by weight of a 55% (w/w) sucrose solution were mixed while heating with 50 parts by weight of a syrup containing a branched cyclotetrasaccharide represented by Chemical Formula 6, obtained by the method in Example A-3. The mixture was then concentrated by heating under a reduced pressure to give a moisture content of less than 2%. The concentrate was mixed with 0.6 part by weight of citric acid and an adequate amount of a lemon flavor, followed by forming the resultant into the desired product in a conventional manner. The product is a stable, high quality hard candy which has a satisfactory mouth feel, taste, and flavor; less adsorbs moisture; and does neither induce crystallization of sucrose nor cause melting.

#### Example B-3: Beverage with lactic acid bacteria

**[0186]** Fifty parts by weight of a syrup containing a branched cyclotetrasaccharide represented by Chemical Formula 7, obtained by the method in Example A-4, and 175 parts by weight of a skim milk powder, and 50 parts by weight of "HYUKAOLIGO™", a high lactosucrose content powder commercialized by Hayashibara Shoji Inc., Okayama, Japan, were dissolved in 1,150 parts by weight of water. The resulting solution was sterilized at 65°C for 30 min, then cooled to 40°C, inoculated in a usual manner with 30 parts by weight of lactic acid bacteria as a starter, and incubated at 37°C for eight hours to obtain a beverage with lactic acid bacteria. The product can be suitably used as a lactic acid beverage which has a satisfactory flavor and taste, contains oligosaccharides and cyclotetrasaccharide, stably retains the lactic acid bacteria, and has actions of promoting the growth of the bacteria and controlling the intestinal conditions.

#### Example B-4: Toothpaste

**[0187]** A syrup containing a branched cyclotetrasaccharide represented by Chemical Formula 1, obtained by the method in Example A-1, was adjusted to a solid concentration of about 30% (w/w). A toothpaste was prepared by mixing 13 parts by weight of water with 15 parts by weight of the above syrup, 45 parts by weight of calcium secondary phosphate, 1.5 parts by weight of sodium lauryl sulfate, 25 parts by weight of glycerol, 0.5 part by weight of polyoxyethylene sorbitan laurate, 0.02 part by weight of saccharine, 0.05 part by weight of an antiseptic, and 13 parts by weight of water. The product has an improved after taste and a satisfactory feeling after use without reducing the detergent power of the surfactant.

#### Example B-5: Bath salt

**[0188]** One part by weight of a peel juice of "yuzu" (a Chinese lemon) was admixed with 10 parts by weight of a branched cyclotetrasaccharide crystal, undeca- or dodeca-hydrate, represented by Chemical Formula 2, obtained by the method in Example A-5, followed by drying and pulverizing the mixture into a powder containing a yuzu peel extract. A bath salt was prepared by mixing five parts by weight of the above powder with 90 parts by weight of grinded salt, two parts by weight of hydrous crystalline trehalose, one part by weight of silicic anhydride, and 0.5 part by weight of "αG HESPERIDIN", an α-glucosyl hesperidin product commercialized by Hayashibara Shoji, Inc., Okayama, Japan. The

product is a bath salt with an elegant, gentle flavor and a superior skin moisturizing effect.

#### Example B-6: Cosmetic cream

**[0189]** Two parts by weight of polyoxyethylene glycol monostearate, five parts by weight of glyceryl monostearate, self-emulsifying, two parts by weight of a branched cyclotetrasaccharide crystal, deca- or undeca-hydrate, represented by Chemical Formula 3, obtained by the method in Example A-6, one part by weight of "αG RUTIN", an α-glucosyl rutin product commercialized by Hayashibara Shoji, Inc., Okayama, Japan, one part by weight of liquid petrolatum, 10 parts by weight of glyceryl tri-2-ethylhexanoate, and an adequate amount of an antiseptic were dissolved by heating in a usual manner. The resulting solution was admixed with two parts by weight of L-lactic acid, five parts by weight of 1,3- butylene glycol, and 66 parts by weight of refined water. The resultant mixture was emulsified by a homogenizer and admixed with an adequate amount of a flavor while stirring to obtain a cosmetic cream. The product exhibits an antioxidant activity and has a relatively high stability, and these render it advantageously useful as a high quality sunscreen, skin-refining agent, and skin-whitening agent.

#### Example B-7: Tablet

**[0190]** Fourteen parts by weight of a branched cyclotetrasaccharide crystal, nona- or deca-hydrate, represented by Chemical Formula 6, obtained by the method in Example A-7, were sufficiently mixed with 50 parts by weight of aspirin and four parts by weight of corn starch. The mixture was then in a conventional manner tabletted by a tabulating machine into a tablet, 680 mg, 5.25 mm in thickness each. The tablet, processed with the filler-imparting ability of the branched cyclotetrasaccharide, has a quite low hygroscopicity, sufficient physical strength, and superior degradability in water.

#### Industrial Applicability

**[0191]** As described above, the present invention was made based on completely novel findings by the present inventors that glycosyl derivatives of cyclotetrasaccharide are formed as by-products of cyclotetrasaccharide when the novel enzymes, i.e., α - isomaltosyl-transferring enzyme and α - isomaltosylglucosaccharide-forming enzyme, which the present inventors had previously found, are allowed to act on starch hydrolyzates; and that a variety of glycosyl derivatives are obtained by allowing saccharide-related enzymes such as the above-identified enzymes, cyclomalto-dextrin glucanotransferase, β - galactosidase, α -galactosidase, and lysozyme to act on cyclotetrasaccharide. Since the glycosyl derivatives provided by the present invention, i.e., branched cyclotetrasaccharides, have the intrinsic properties of cyclotetrasaccharide such as an inclusion ability and substantially non-digestibility, they can be advantageously used in a various fields of foods and beverages, cosmetics, and pharmaceuticals similarly as cyclotetrasaccharide. Advanced analysis of physical and chemical properties and functions of the branched cyclotetrasaccharides of the present invention will give an important finding that leads to development of novel uses of cyclotetrasaccharide and improvement of the properties and functions thereof.

**[0192]** The present invention with these outstanding functions and effects is a significant and important invention that greatly contributes to this art.

## SEQUENCE LISTING

5 <110> Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo

<120> Branched cyclic tetrasaccharides, their preparations and uses

10 <130> 2

15 <160> W0889

<210> 1

20 <211> 3282

<212> DNA

<213> Bacillus globisporus

25 <220>

<221> CDS

<222> (1)... (3282)

30 <220>

<221> sig\_peptide

35 <222> (1)... (87)

<400> 1

40 atg tat gta agg aat cta aca ggt tca ttc cga ttt tct ctc tct ttt 48  
Met Tyr Val Arg Asn Leu Thr Gly Ser Phe Arg Phe Ser Leu Ser Phe  
1 5 10 15

45 ttg ctc tgt ttc tgt ctc ttc gtc ccc tct att tat gcc att gat ggt 96  
Leu Leu Cys Phe Cys Leu Phe Val Pro Ser Ile Tyr Ala Ile Asp Gly  
20 25 30

50 gtt tat cat gcg cca tac gga atc gat gat ctc tac gag att cag gcg 144  
Val Tyr His Ala Pro Tyr Gly Ile Asp Asp Leu Tyr Glu Ile Gln Ala  
35 40 45

55 acg gag cgg agt cca aga gat ccc gtt gca ggc gal act gtg tat atc 192  
Thr Glu Arg Ser Pro Arg Asp Pro Val Ala Gly Asp Thr Val Tyr Ile  
50 55 60

	aag ata aca acg tgg ccc att gaa tca gga caa acg gct tgg gtg acc	240
5	Lys Ile Thr Thr Trp Pro Ile Glu Ser Gly Gln Thr Ala Trp Val Thr	
	65 70 75 80	
	tgg acg aaa aac ggt gtc aat caa gct gct gtc gga gca gca ttc aaa	288
10	Trp Thr Lys Asn Gly Val Asn Gln Ala Ala Val Gly Ala Ala Phe Lys	
	85 90 95	
	tac aac agc ggc aac aac act tac tgg gaa gcg aac ctt ggc act ttt	336
15	Tyr Asn Ser Gly Asn Asn Thr Tyr Trp Glu Ala Asn Leu Gly Thr Phe	
	100 105 110	
	gca aaa ggg gac gtg atc agt tat acc gtt cat ggc aac aag gat ggc	384
20	Ala Lys Gly Asp Val Ile Ser Tyr Thr Val His Gly Asn Lys Asp Gly	
	115 120 125	
	gcg aat gag aag gtt atc ggt cct ttt act ttt acc gta acg gga tgg	432
25	Ala Asn Glu Lys Val Ile Gly Pro Phe Thr Phe Thr Val Thr Gly Trp	
	130 135 140	
	gaa tcc gtt agc agt atc agc tct att acg gat aat acg aac cgt gtt	480
30	Glu Ser Val Ser Ser Ile Ser Ser Ile Thr Asp Asn Thr Asn Arg Val	
	145 150 155 160	
	gtg ctg aat gcg gtg ccg aat aca ggc aca ttg aag cca aag atc aac	528
35	Val Leu Asn Ala Val Pro Asn Thr Gly Thr Leu Lys Pro Lys Ile Asn	
	165 170 175	
	ctt tcc ttt acg gcg gat gat gtc ctc cgc gta cag gtt tct cca acc	576
40	Leu Ser Phe Thr Ala Asp Asp Val Leu Arg Val Gln Val Ser Pro Thr	
	180 185 190	
	gga aca gga acg tia agc agt gga ctt agt aat tac aca gtt tca gat	624
45	Gly Thr Gly Thr Leu Ser Ser Gly Leu Ser Asn Tyr Thr Val Ser Asp	
	195 200 205	
	acc gcc tca acc act tgg ctt aca act tcc aag ctg aag gtg aag gtg	672
50	Thr Ala Ser Thr Thr Trp Leu Thr Thr Ser Lys Leu Lys Val Lys Val	
	210 215 220	
	gat aag aat cca ttc aaa ctt agt gtg tat aag cct gat gga acg acg	720
55	Asp Lys Asn Pro Phe Lys Leu Ser Val Tyr Lys Pro Asp Gly Thr Thr	
	225 230 235 240	
	ttg att gcc cgt caa tat gac agc act acg aat cgt aac att gcc tgg	768
	Leu Ile Ala Arg Gln Tyr Asp Ser Thr Thr Asn Arg Asn Ile Ala Trp	
	245 250 255	

EP 1 380 595 A1

	tta acc aat ggc agt aca aic aic gac aag gta gaa gat cat ttt tat	816
	Leu Thr Asn Gly Ser Thr Ile Ile Asp Lys Val Glu Asp His Phe Tyr	
5	260 265 270	
	tca ccg gct tcc gag gag ttt ttt ggc ttt gga gag cat tac aac aac	864
	Ser Pro Ala Ser Glu Glu Phe Phe Gly Phe Gly Glu His Tyr Asn Asn	
10	275 280 285	
	ttc cgt aaa cgc gga aat gat gtg gac acc tat gtg ttc aac cag tat	912
	Phe Arg Lys Arg Gly Asn Asp Val Asp Thr Tyr Val Phe Asn Gln Tyr	
15	290 295 300	
	aag aat caa aat gac cgc acc tac atg gca att cct ttt atg ctt aac	960
	Lys Asn Gln Asn Asp Arg Thr Tyr Met Ala Ile Pro Phe Met Leu Asn	
20	305 310 315 320	
	agc agc ggt tat ggc att ttc gta aat tca acg tat tat tcc aaa ttt	1008
	Ser Ser Gly Tyr Gly Ile Phe Val Asn Ser Thr Tyr Tyr Ser Lys Phe	
	325 330 335	
25	cgg ttg gca acc gaa cgc acc gat atg ttc agc ttt acg gct gat aca	1056
	Arg Leu Ala Thr Glu Arg Thr Asp Met Phe Ser Phe Thr Ala Asp Thr	
	340 345 350	
30	ggg ggt agt gcc gcc tcg atg ctg gat tat tat ttc att tac ggt aat	1104
	Gly Gly Ser Ala Ala Ser Met Leu Asp Tyr Tyr Phe Ile Tyr Gly Asn	
	355 360 365	
	gat ttg aaa aat gtg gtg agt aac tac gct aac att acc ggt aag cca	1152
35	Asp Leu Lys Asn Val Val Ser Asn Tyr Ala Asn Ile Thr Gly Lys Pro	
	370 375 380	
	aca gcg ctg ccg aaa tgg gct ttc ggg tta tgg atg tca gct aac gag	1200
40	Thr Ala Leu Pro Lys Trp Ala Phe Gly Leu Trp Met Ser Ala Asn Glu	
	385 390 395 400	
	tgg gat cgt caa acc aag gtg aat aca gcc att aat aac gcg aac tcc	1248
45	Trp Asp Arg Gln Thr Lys Val Asn Thr Ala Ile Asn Asn Ala Asn Ser	
	405 410 415	
	aat aat att ccg gct aca gcg gtt gtg ctc gaa cag tgg agt gat gag	1296
	Asn Asn Ile Pro Ala Thr Ala Val Val Leu Glu Gln Trp Ser Asp Glu	
50	420 425 430	
	aac acg ttt tat att ttc aat gat gcc acc tat acc ccg aaa acg ggc	1344
	Asn Thr Phe Tyr Ile Phe Asn Asp Ala Thr Tyr Thr Pro Lys Thr Gly	
55	435 440 445	



	agi gci gcg cat gcc tat acc gat ttc act ttc ccg aca tct ggg aga	1393
	Ser Ala Ala His Ala Tyr Thr Asp Phe Thr Phe Pro Thr Ser Gly Arg	
5	450 455 460	
	tgg acg gat cca aaa gcg atg gca gac aat gig cat aac aat ggg atg	1440
	Trp Thr Asp Pro Lys Ala Met Ala Asp Asn Val His Asn Asn Gly Met	
10	465 470 475 480	
	aag cig gtg ctt tgg cag gtc cct att cag aaa tgg act tca acg ccc	1488
	Lys Leu Val Leu Trp Gln Val Pro Ile Gln Lys Trp Thr Ser Thr Pro	
15	485 490 495	
	tat acc cag aaa gat aat gat gaa gcc tat atg acg gct cag aat tat	1536
	Tyr Thr Gln Lys Asp Asn Asp Glu Ala Tyr Met Thr Ala Gln Asn Tyr	
20	500 505 510	
	gca gtt ggc aac ggt agc gga ggc cag tac agg ata cct tca gga caa	1584
	Ala Val Gly Asn Gly Ser Gly Gly Gln Tyr Arg Ile Pro Ser Gly Gln	
	515 520 525	
25	tgg ttc gag aac agt ttg ctg ctt gat ttt acg aat acg gcc gcc aaa	1632
	Trp Phe Glu Asn Ser Leu Leu Leu Asp Phe Thr Asn Thr Ala Ala Lys	
	530 535 540	
30	aac tgg tgg atg tct aaa cgc gct tat ctg ttt gat ggt gtg ggt atc	1680
	Asn Trp Trp Met Ser Lys Arg Ala Tyr Leu Phe Asp Gly Val Gly Ile	
	545 550 555 560	
35	gac ggc ttc aaa aca gat ggc ggt gaa atg gta tgg ggt cgc tca aat	1728
	Asp Gly Phe Lys Thr Asp Gly Gly Glu Met Val Trp Gly Arg Ser Asn	
	565 570 575	
40	act ttc tca aac ggt aag aaa ggc aat gaa atg cgc aat caa tac ccg	1776
	Thr Phe Ser Asn Gly Lys Lys Gly Asn Glu Met Arg Asn Gln Tyr Pro	
	580 585 590	
45	aat gag tat gtg aaa gcc tat aac gag tac gcg cgc tcg aag aaa gcc	1824
	Asn Glu Tyr Val Lys Ala Tyr Asn Glu Tyr Ala Arg Ser Lys Lys Ala	
	595 600 605	
50	gat gcg gtc tcc ttt agc cgt tcc ggc acg caa ggc gca cag gcg aat	1872
	Asp Ala Val Ser Phe Ser Arg Ser Gly Thr Gln Gly Ala Gln Ala Asn	
	610 615 620	
	cag att ttc tgg tcc ggt gac caa gag tcg acg ttt ggt gct ttt caa	1920
	Gln Ile Phe Trp Ser Gly Asp Gln Glu Ser Thr Phe Gly Ala Phe Gln	
55	625 630 635 640	

	caa gcl gig aat gca ggg ctt acg gca agt atg tct ggc gtt cct tat	1968
5	Gln Ala Val Asn Ala Gly Leu Thr Ala Ser Met Ser Gly Val Pro Tyr	
	645 650 655	
	tgg agc lgg gat atg gca ggc ttt aca ggc act tat cca acg gct gag	2016
10	Trp Ser Trp Asp Met Ala Gly Phe Thr Gly Thr Tyr Pro Thr Ala Glu	
	660 665 670	
	ttg tac aaa cgt gcl act gaa atg gct gct ttt gca ccg gtc atg cag	2064
15	Leu Tyr Lys Arg Ala Thr Glu Met Ala Ala Phe Ala Pro Val Met Gln	
	675 680 685	
	ttt cat tcc gag tct aac ggc agc tct ggt atc aac gag gaa cgt tct	2112
20	Phe His Ser Glu Ser Asn Gly Ser Ser Gly Ile Asn Glu Glu Arg Ser	
	690 695 700	
	cca tgg aac gca caa gcg cgt aca ggc gac aat acg atc att agt cal	2160
25	Pro Trp Asn Ala Gln Ala Arg Thr Gly Asp Asn Thr Ile Ile Ser His	
	705 710 715 720	
	ttt gcc aaa tat acg aat acg cgc atg aat ttg ctt cct tat att tat	2208
30	Phe Ala Lys Tyr Thr Asn Thr Arg Met Asn Leu Leu Pro Tyr Ile Tyr	
	725 730 735	
	agc gaa gcg aag atg gct agt gat act ggc gtt ccc atg atg cgc gcc	2256
35	Ser Glu Ala Lys Met Ala Ser Asp Thr Gly Val Pro Met Met Arg Ala	
	740 745 750	
	atg gcg ctt gaa tat ccg aag gac acg aac acg tac ggt ttg aca caa	2304
40	Met Ala Leu Glu Tyr Pro Lys Asp Thr Asn Thr Tyr Gly Leu Thr Gln	
	755 760 765	
	cag tat atg ttc gga ggt aat tta ctt att gct cct gtt atg aat cag	2352
45	Gln Tyr Met Phe Gly Gly Asn Leu Leu Ile Ala Pro Val Met Asn Gln	
	770 775 780	
	gga gaa aca aac aag agt att tat ctt ccg cag ggg gat tgg atc gat	2400
50	Gly Glu Thr Asn Lys Ser Ile Tyr Leu Pro Gln Gly Asp Trp Ile Asp	
	785 790 795 800	
	ttc tgg ttc ggt gcl cag cgt cct ggc ggt cga aca atc agc tac acg	2448
55	Phe Trp Phe Gly Ala Gln Arg Pro Gly Gly Arg Thr Ile Ser Tyr Thr	
	805 810 815	
	gcc ggc atc gat gal cia ccg gtt ttt gtg aag ttt ggc agt att ctt	2496
	Ala Gly Ile Asp Asp Leu Pro Val Phe Val Lys Phe Gly Ser Ile Leu	
	820 825 830	

	ccg atg aat ttg aac gcg caa tat caa gtc ggc ggg acc att ggc aac	2544
5	Pro Met Asn Leu Asn Ala Gln Tyr Gln Val Gly Gly Thr Ile Gly Asn	
	835 840 845	
	agc ttg acg agc tac acg aat ctg gcg ttc cgc att tat ccg ctt ggg	2592
10	Ser Leu Thr Ser Tyr Thr Asn Leu Ala Phe Arg Ile Tyr Pro Leu Gly	
	850 855 860	
	aca aca acg tac gac tgg aat gat gat att ggc ggt tgc gtc aaa acc	2640
15	Thr Thr Thr Tyr Asp Trp Asn Asp Asp Ile Gly Gly Ser Val Lys Thr	
	865 870 875 880	
	ata act tct aca gag caa tat ggg ttg aat aaa gaa acc gtc act gtt	2688
20	Ile Thr Ser Thr Glu Gln Tyr Gly Leu Asn Lys Glu Thr Val Thr Val	
	885 890 895	
	cca gcg att aat tct acc aag aca ttg caa gtc ttt acg act aag cct	2736
25	Pro Ala Ile Asn Ser Thr Lys Thr Leu Gln Val Phe Thr Thr Lys Pro	
	900 905 910	
	tcc tct gta acg gtc ggt ggt tct gtc atg aca gag tac agt act tta	2784
30	Ser Ser Val Thr Val Gly Gly Ser Val Met Thr Glu Tyr Ser Thr Leu	
	915 920 925	
	act gcc cta acg gga gcg tgc aca ggc tgg tac tat gat act gta cag	2832
35	Thr Ala Leu Thr Gly Ala Ser Thr Gly Trp Tyr Tyr Asp Thr Val Gln	
	930 935 940	
	aaa ttc act tac gtc aag ctt ggt tca agt gca tct gct caa tcc gtt	2880
40	Lys Phe Thr Tyr Val Lys Leu Gly Ser Ser Ala Ser Ala Gln Ser Val	
	945 950 955 960	
	gtg cta aat ggc gtt aat aag gtc gaa tat gaa gca gaa ttc ggc gtc	2928
45	Val Leu Asn Gly Val Asn Lys Val Glu Tyr Glu Ala Glu Phe Gly Val	
	965 970 975	
	caa agc ggc gtt tca acg aac acg aac cat gca ggt tat act ggt aca	2976
50	Gln Ser Gly Val Ser Thr Asn Thr Asn His Ala Gly Tyr Thr Gly Thr	
	980 985 990	
	gga ttt gtc gac ggc ttt gag act ctt gga gac aat gtt gct ttt gat	3024
55	Gly Phe Val Asp Gly Phe Glu Thr Leu Gly Asp Asn Val Ala Phe Asp	
	995 1000 1005	
	ggt tcc gtc aaa gcc gca ggt act tat acg atg aag gtt cgg tat tca	3072
	Val Ser Val Lys Ala Ala Gly Thr Tyr Thr Met Lys Val Arg Tyr Ser	
	1010 1015 1020	

EP 1 380 595 A1

1cc ggt gca ggc aat ggc tca aga gcc atc tat gtg aat aac acc aaa 3120  
 Ser Gly Ala Gly Asn Gly Ser Arg Ala Ile Tyr Val Asn Asn Thr Lys  
 5 1025 1030 1035 1040  
 gig acg gac ctt gcc ttg ccg caa aca aca agc tgg gat aca tgg ggg 3168  
 Val Thr Asp Leu Ala Leu Pro Gln Thr Thr Ser Trp Asp Thr Trp Gly  
 10 1045 1050 1055  
 act gct acg ttt agc gtc tgc ctg agt aca ggt ctc aac acg gtg aaa 3216  
 Thr Ala Thr Phe Ser Val Ser Leu Ser Thr Gly Leu Asn Thr Val Lys  
 15 1060 1065 1070  
 gtc agc tat gat ggt acc agt tca ctt ggc att aat ttc gat aac atc 3264  
 Val Ser Tyr Asp Gly Thr Ser Ser Leu Gly Ile Asn Phe Asp Asn Ile  
 1075 1080 1085  
 20 gcg att gta gag caa taa 3282  
 Ala Ile Val Glu Gln  
 1090  
 25  
 <210> 2  
 <211> 3855  
 <212> DNA  
 30 <213> *Bacillus globisporus*  
 <220>  
 35 <221> CDS  
 <222> (1)... (3855)  
 <220>  
 40 <221> sig\_peptide  
 <222> (1)... (105)  
 45 <400> 2  
 atg cgt cca cca aac aaa gaa att cca cgt att ctt gct ttt ttt aca 48  
 Met Arg Pro Pro Asn Lys Glu Ile Pro Arg Ile Leu Ala Phe Phe Thr  
 50 1 5 10 15  
 gcg ttt acg ttg ttt ggt tca acc ctt gcc ttg ctt cct gct ccg cct 96  
 Ala Phe Thr Leu Phe Gly Ser Thr Leu Ala Leu Leu Pro Ala Pro Pro  
 55 20 25 30

	gcg cat gcc tal gtc agc agc cta gga aat ctc att tct tcg agt gtc	144
	Ala His Ala Tyr Val Ser Ser Leu Gly Asn Leu Ile Ser Ser Ser Val	
5	35 40 45	
	acc gga gat acc ttg acg cta act gtt gat aac ggt gcg gag ccg agt	192
	Thr Gly Asp Thr Leu Thr Leu Thr Val Asp Asn Gly Ala Glu Pro Ser	
10	50 55 60	
	gat gac ctc ttg att gtt caa gcg gtg caa aac ggt att ttg aag gtg	240
	Asp Asp Leu Leu Ile Val Gln Ala Val Gln Asn Gly Ile Leu Lys Val	
15	65 70 75 80	
	gat tat cgt cca aat agc ata acg ccg agc gcg aag acg ccg atg ctg	288
	Asp Tyr Arg Pro Asn Ser Ile Thr Pro Ser Ala Lys Thr Pro Met Leu	
	85 90 95	
20	gat ccg aac aaa act tgg tca gct gla gga gct acg att aat acg aca	336
	Asp Pro Asn Lys Thr Trp Ser Ala Val Gly Ala Thr Ile Asn Thr Thr	
	100 105 110	
25	gcc aat cca atg acc atc acg act tcc aat atg aag att gag att acc	384
	Ala Asn Pro Met Thr Ile Thr Thr Ser Asn Met Lys Ile Glu Ile Thr	
	115 120 125	
30	aag aat cca gta cga atg acg gtc aag aag gcg gac ggc act acg cta	432
	Lys Asn Pro Val Arg Met Thr Val Lys Lys Ala Asp Gly Thr Thr Leu	
	130 135 140	
35	ttc tgg gaa cca tca ggc gga ggg gla ttc tca gac ggt gtg cgc ttc	480
	Phe Trp Glu Pro Ser Gly Gly Gly Val Phe Ser Asp Gly Val Arg Phe	
	145 150 155 160	
	cit cat gcc aca ggg gat aat atg tal ggc atc cgg agc ttc aat gct	528
	Leu His Ala Thr Gly Asp Asn Met Tyr Gly Ile Arg Ser Phe Asn Ala	
40	165 170 175	
	ttt gat agc ggg ggt gac ctg ctg cgg aat tcc tcc aat cat gcc gcc	576
	Phe Asp Ser Gly Gly Asp Leu Leu Arg Asn Ser Ser Asn His Ala Ala	
45	180 185 190	
	cat gcg ggt gaa cag gga gat tcc ggt ggt ccg ctt att tgg agt acg	624
	His Ala Gly Glu Gln Gly Asp Ser Gly Gly Pro Leu Ile Trp Ser Thr	
50	195 200 205	
	gca gga tat gga cta tta gtc gat agc gat ggc ggc tac ccc tat aca	672
	Ala Gly Tyr Gly Leu Leu Val Asp Ser Asp Gly Gly Tyr Pro Tyr Thr	
55	210 215 220	

EP 1 380 595 A1

	gat agc aca acc ggt caa atg gag ttt tat tat ggt ggg acc cct cct	720
	Asp Ser Thr Thr Gly Gln Met Glu Phe Tyr Tyr Gly Gly Thr Pro Pro	
5	225 230 235 240	
	gag gga cgt cgt tat gcg aaa caa aac gtg gaa tat tat att atg ctc	768
	Glu Gly Arg Arg Tyr Ala Lys Gln Asn Val Glu Tyr Tyr Ile Met Leu	
10	245 250 255	
	gga acc ccc aag gaa att atg acc gac gta ggg gaa atc aca ggg aaa	816
	Gly Thr Pro Lys Glu Ile Met Thr Asp Val Gly Glu Ile Thr Gly Lys	
15	260 265 270	
	ccg cct atg ctg cct aag tgg tcg ctt gga ttc atg aac ttt gag tgg	864
	Pro Pro Met Leu Pro Lys Trp Ser Leu Gly Phe Met Asn Phe Glu Trp	
20	275 280 285	
	gat acg aat caa acg gag ttt acg aat aat gtg gat acg tat cgt gcc	912
	Asp Thr Asn Gln Thr Glu Phe Thr Asn Asn Val Asp Thr Tyr Arg Ala	
25	290 295 300	
	aaa aat atc ccc ata gat gct tac gcc ttc gac tat gac tgg aaa aag	960
	Lys Asn Ile Pro Ile Asp Ala Tyr Ala Phe Asp Tyr Asp Trp Lys Lys	
30	305 310 315 320	
	tac ggg gaa acc aac tat ggt gaa ttc gcg tgg aat acg act aat ttc	1008
	Tyr Gly Glu Thr Asn Tyr Gly Glu Phe Ala Trp Asn Thr Thr Asn Phe	
35	325 330 335	
	cct tct gcg tca acg act tct tta aag tca aca atg gat gct aaa ggc	1056
	Pro Ser Ala Ser Thr Thr Ser Leu Lys Ser Thr Met Asp Ala Lys Gly	
40	340 345 350	
	atc aaa atg atc gga att aca aaa ccc cgc atc gtt acg aag gat gct	1104
	Ile Lys Met Ile Gly Ile Thr Lys Pro Arg Ile Val Thr Lys Asp Ala	
45	355 360 365	
	tca gcg aat gtg acg acc caa ggg acg gac gcg aca aat ggc ggt tat	1152
	Ser Ala Asn Val Thr Thr Gln Gly Thr Asp Ala Thr Asn Gly Gly Tyr	
50	370 375 380	
	ttt tat cca ggc cat aac gag tat cag gat tat ttc att ccc gta act	1200
	Phe Tyr Pro Gly His Asn Glu Tyr Gln Asp Tyr Phe Ile Pro Val Thr	
55	385 390 395 400	
	gtg cgt agt atc gat cct tac aat gct aac gaa cgt gct tgg ttc tgg	1248
	Val Arg Ser Ile Asp Pro Tyr Asn Ala Asn Glu Arg Ala Trp Phe Trp	
	405 410 415	

	aat	cai	icc	aca	gat	gcg	ctt	aat	aaa	ggg	atc	gta	ggt	tgg	tgg	aat	1296
5	Asn	His	Ser	Thr	Asp	Ala	Leu	Asn	Lys	Gly	Ile	Val	Gly	Trp	Trp	Asn	
				420				425					430				
	gac	gag	acg	gal	aaa	gia	tct	tcg	ggt	gga	gcg	tta	tal	tgg	ttt	ggc	1344
10	Asp	Glu	Thr	Asp	Lys	Val	Ser	Ser	Gly	Gly	Ala	Leu	Tyr	Trp	Phe	Gly	
				435				440					445				
	aat	ttc	aca	aca	ggc	cac	atg	tct	cag	acg	atg	tac	gaa	ggg	ggg	cgg	1393
15	Asn	Phe	Thr	Thr	Gly	His	Met	Ser	Gln	Thr	Met	Tyr	Glu	Gly	Gly	Arg	
				450				455					460				
	gct	tac	acg	agt	gga	gcg	cag	cgt	gtt	tgg	caa	acg	gct	aga	acc	ttc	1440
20	Ala	Tyr	Thr	Ser	Gly	Ala	Gln	Arg	Val	Trp	Gln	Thr	Ala	Arg	Thr	Phe	
				465				470					475			480	
	tac	cca	ggt	gcc	cag	cgg	tat	gcg	act	acg	cit	tgg	tct	ggc	gal	att	1488
25	Tyr	Pro	Gly	Ala	Gln	Arg	Tyr	Ala	Thr	Thr	Leu	Trp	Ser	Gly	Asp	Ile	
				485				490					495				
	ggc	att	caa	tac	aat	aaa	ggc	gaa	cgg	atc	aat	tgg	gct	gcc	ggg	atg	1536
30	Gly	Ile	Gln	Tyr	Asn	Lys	Gly	Glu	Arg	Ile	Asn	Trp	Ala	Ala	Gly	Met	
				500				505					510				
	cag	gag	caa	agg	gca	gtt	atg	cta	tcc	tcc	gtg	aac	aat	ggc	cag	gtg	1584
35	Gln	Glu	Gln	Arg	Ala	Val	Met	Leu	Ser	Ser	Val	Asn	Asn	Gly	Gln	Val	
				515				520					525				
	aaa	tgg	ggc	atg	gat	acc	ggc	gga	ttc	aat	cag	cag	gat	ggc	acg	acg	1632
40	Lys	Trp	Gly	Met	Asp	Thr	Gly	Gly	Phe	Asn	Gln	Gln	Asp	Gly	Thr	Thr	
				530				535					540				
	aac	aat	ccg	aat	ccc	gat	tta	tac	gct	cgg	tgg	atg	cag	ttc	agt	gcc	1680
45	Asn	Asn	Pro	Asn	Pro	Asp	Leu	Tyr	Ala	Arg	Trp	Met	Gln	Phe	Ser	Ala	
				545				550					555			560	
	cta	acg	cct	gtt	ttc	cga	gtg	cat	ggg	aac	aac	cat	cag	cag	cgc	cag	1728
50	Leu	Thr	Pro	Val	Phe	Arg	Val	His	Gly	Asn	Asn	His	Gln	Gln	Arg	Gln	
				565				570					575				
	cca	tgg	tac	ttc	gga	tcg	act	gcg	gag	gag	gcc	tcc	aaa	gag	gca	att	1776
55	Pro	Trp	Tyr	Phe	Gly	Ser	Thr	Ala	Glu	Glu	Ala	Ser	Lys	Glu	Ala	Ile	
				580				585					590				
	cag	ctg	cgg	tac	tcc	ctg	atc	ccf	tat	atg	tat	gcc	tat	gag	aga	agt	1824
60	Gln	Leu	Arg	Tyr	Ser	Leu	Ile	Pro	Tyr	Met	Tyr	Ala	Tyr	Glu	Arg	Ser	
				595				600					605				



	gct tac gag aat ggg aat ggg ctc gti cgg cca ttg atg caa gcc tat	1872
	Ala Tyr Glu Asn Gly Asn Gly Leu Val Arg Pro Leu Met Gln Ala Tyr	
5	610 615 620	
	cca aca gat gcg gcc gtc aaa aat tac acg gat gct tgg atg ttt ggt	1920
	Pro Thr Asp Ala Ala Val Lys Asn Tyr Thr Asp Ala Trp Met Phe Gly	
10	625 630 635 640	
	gac tgg ctg ctg gct gca cct glg gta gat aaa cag cag acg agt aag	1968
	Asp Trp Leu Leu Ala Ala Pro Val Val Asp Lys Gln Gln Thr Ser Lys	
15	645 650 655	
	gat atc tat tta ccg tct ggg tca tgg att gac tat gcg cga ggc aat	2016
	Asp Ile Tyr Leu Pro Ser Gly Ser Trp Ile Asp Tyr Ala Arg Gly Asn	
20	660 665 670	
	gca ata act ggc ggt caa acc atc cga tat tcg gtt aat ccg gac acg	2064
	Ala Ile Thr Gly Gly Gln Thr Ile Arg Tyr Ser Val Asn Pro Asp Thr	
25	675 680 685	
	ttg aca gac atg cct ctc tti att aaa aaa ggt gcc att att cca aca	2112
	Leu Thr Asp Met Pro Leu Phe Ile Lys Lys Gly Ala Ile Ile Pro Thr	
30	690 695 700	
	cag aaa gtc cag gat tac gta ggg cag gct tcc gtc act tcc gtt gat	2160
	Gln Lys Val Gln Asp Tyr Val Gly Gln Ala Ser Val Thr Ser Val Asp	
35	705 710 715 720	
	gtg gat gtg ttt ccg gat acg acg cag tcg agt ttc acg tac tac gat	2208
	Val Asp Val Phe Pro Asp Thr Thr Gln Ser Ser Phe Thr Tyr Tyr Asp	
40	725 730 735	
	gat gat ggc gcc agt tat aac tat gag agc ggc act tat ttt aag caa	2256
	Asp Asp Gly Ala Ser Tyr Asn Tyr Glu Ser Gly Thr Tyr Phe Lys Gln	
45	740 745 750	
	aat atg act gct cag gat aat ggg tca ggc tcg tta agt ttt act tta	2304
	Asn Met Thr Ala Gln Asp Asn Gly Ser Gly Ser Leu Ser Phe Thr Leu	
50	755 760 765	
	gga gca aag agt ggc agt tac acg ccg gct ctc caa tcc tat atc gtt	2352
	Gly Ala Lys Ser Gly Ser Tyr Thr Pro Ala Leu Gln Ser Tyr Ile Val	
55	770 775 780	
	aag ctg cac ggt tct gct gga act tct gtt acg aat aac agc gca gct	2400
	Lys Leu His Gly Ser Ala Gly Thr Ser Val Thr Asn Asn Ser Ala Ala	
	785 790 795 800	

	aig aca tct tat gca agc tlg gaa gca tta aaa gct gct gct ggg gaa	2448
	Met Thr Ser Tyr Ala Ser Leu Glu Ala Leu Lys Ala Ala Ala Gly Glu	
5	805 810 815	
	ggc tgg gcg act ggg aag gac att tat ggg gat gtc acc tat gtg aaa	2496
	Gly Trp Ala Thr Gly Lys Asp Ile Tyr Gly Asp Val Thr Tyr Val Lys	
10	820 825 830	
	gtg acg gca ggt aca gct tct tct aaa tct att gct gtt aca ggt gtt	2544
	Val Thr Ala Gly Thr Ala Ser Ser Lys Ser Ile Ala Val Thr Gly Val	
15	835 840 845	
	gct gcc gtg agc gca act act tcg caa tac gaa gct gag gat gca tcg	2592
	Ala Ala Val Ser Ala Thr Thr Ser Gln Tyr Glu Ala Glu Asp Ala Ser	
20	850 855 860	
	ctt tct ggc aat tcg gtt gct gca aag gcg tcc ata aac acg aat cat	2640
	Leu Ser Gly Asn Ser Val Ala Ala Lys Ala Ser Ile Asn Thr Asn His	
25	865 870 875 880	
	acc gga tat acg gga act gga ttt gta gat ggt ttg ggg aat gat ggc	2688
	Thr Gly Tyr Thr Gly Thr Gly Phe Val Asp Gly Leu Gly Asn Asp Gly	
30	885 890 895	
	gct ggt gtc acc ttc tat cca aag gtg aaa act ggc ggt gac tac aat	2736
	Ala Gly Val Thr Phe Tyr Pro Lys Val Lys Thr Gly Gly Asp Tyr Asn	
35	900 905 910	
	gtc tcc tlg cgt tat gcg aat gct tca ggc acg gct aag tca gtc agt	2784
	Val Ser Leu Arg Tyr Ala Asn Ala Ser Gly Thr Ala Lys Ser Val Ser	
40	915 920 925	
	att ttt gtt aat gga aaa aga gtg aag tcc acc tcg ctc gct aat ctc	2832
	Ile Phe Val Asn Gly Lys Arg Val Lys Ser Thr Ser Leu Ala Asn Leu	
45	930 935 940	
	gca aat tgg gac act tgg tct aca caa tct gag aca ctg ccg tlg acg	2880
	Ala Asn Trp Asp Thr Trp Ser Thr Gln Ser Glu Thr Leu Pro Leu Thr	
50	945 950 955 960	
	gca ggt glg aat gtt gtg acc tat aaa tat tac tcc gat gcg gga gat	2928
	Ala Gly Val Asn Val Val Thr Tyr Lys Tyr Tyr Ser Asp Ala Gly Asp	
55	965 970 975	
	aca ggc aat gtt aac atc gac aac atc acg gla cct ttt gcg cca att	2976
	Thr Gly Asn Val Asn Ile Asp Asn Ile Thr Val Pro Phe Ala Pro Ile	
	980 985 990	

	atc ggt aag tat gaa gca gag agt gct gag ctt tct ggt ggc agc tca	3024
	Ile Gly Lys Tyr Glu Ala Glu Ser Ala Glu Leu Ser Gly Gly Ser Ser	
5	995 1000 1005	
	ttg aac acg aac cat tgg tac tac agt ggt acg gct ttt gta gac ggt	3072
	Leu Asn Thr Asn His Trp Tyr Tyr Ser Gly Thr Ala Phe Val Asp Gly	
10	1010 1015 1020	
	ttg agt gct gta ggc gcg cag gtg aaa tac aac gtg aat gtc cct agc	3120
	Leu Ser Ala Val Gly Ala Gln Val Lys Tyr Asn Val Asn Val Pro Ser	
15	1025 1030 1035 1040	
	gca gga agt tat cag gta gcg ctg cga tai gcg aat ggc agt gca gcg	3168
	Ala Gly Ser Tyr Gln Val Ala Leu Arg Tyr Ala Asn Gly Ser Ala Ala	
	1045 1050 1055	
20	acg aaa acg ttg agt act tat atc aat gga gcc aag ctg ggg caa acc	3216
	Thr Lys Thr Leu Ser Thr Tyr Ile Asn Gly Ala Lys Leu Gly Gln Thr	
	1060 1065 1070	
25	agt ttt acg agt cct ggt acg aat tgg aat gtt tgg cag gat aat gtg	3264
	Ser Phe Thr Ser Pro Gly Thr Asn Trp Asn Val Trp Gln Asp Asn Val	
	1075 1080 1085	
30	caa acg gtg acg tta aat gca ggg gca aac acg att gcg ttt aaa tac	3312
	Gln Thr Val Thr Leu Asn Ala Gly Ala Asn Thr Ile Ala Phe Lys Tyr	
	1090 1095 1100	
35	gac gcc gct gac agc ggg aac atc aac gta gat cgt ctg ctt ctt tca	3360
	Asp Ala Ala Asp Ser Gly Asn Ile Asn Val Asp Arg Leu Leu Leu Ser	
	1105 1110 1115 1120	
	act tcg gca gcg gga acg ccg gtt tct gag cag aac ctg cta gac aat	3408
40	Thr Ser Ala Ala Gly Thr Pro Val Ser Glu Gln Asn Leu Leu Asp Asn	
	1125 1130 1135	
45	ccc ggt ttc gag cgt gac acg agt caa acc aat aac tgg att gag tgg	3456
	Pro Gly Phe Glu Arg Asp Thr Ser Gln Thr Asn Asn Trp Ile Glu Trp	
	1140 1145 1150	
	cat cca ggc acg caa gct gtt gct ttt ggc gtt gat agc ggc tca acc	3504
50	His Pro Gly Thr Gln Ala Val Ala Phe Gly Val Asp Ser Gly Ser Thr	
	1155 1160 1165	
	acc aat ccg ccg gaa tcc ccg tgg tcg ggt gat aag cgt gcc tac ttc	3552
	Thr Asn Pro Pro Glu Ser Pro Trp Ser Gly Asp Lys Arg Ala Tyr Phe	
55	1170 1175 1180	

5           ttt gca gca ggt gcc tat caa caa agc atc cat caa acc att agt gtt   3600  
           Phe Ala Ala Gly Ala Tyr Gln Gln Ser Ile His Gln Thr Ile Ser Val  
           1185                           1190                           1195                           1200  
 10           cct gtt aat aat gta aaa tac aaa ttt gaa gcc tgg gtc cgc atg aag   3648  
           Pro Val Asn Asn Val Lys Tyr Lys Phe Glu Ala Trp Val Arg Met Lys  
                                   1205                           1210                           1215  
           aat acg acg ccg acg acg gca aga gcc gaa att caa aac tat ggc gga   3696  
           Asn Thr Thr Pro Thr Thr Ala Arg Ala Glu Ile Gln Asn Tyr Gly Gly  
                                   1220                           1225                           1230  
 15           tca gcc att tat gcg aac ata agt aac agc ggt gtt tgg aaa tat atc   3744  
           Ser Ala Ile Tyr Ala Asn Ile Ser Asn Ser Gly Val Trp Lys Tyr Ile  
                                   1235                           1240                           1245  
 20           agc gta agt gat att atg gtg acc aat ggt cag ata gat gtt gga ttt   3792  
           Ser Val Ser Asp Ile Met Val Thr Asn Gly Gln Ile Asp Val Gly Phe  
                                   1250                           1255                           1260  
 25           tac gtg gat tca cct ggt gga act acg ctt cac att gal gat gtg cgc   3840  
           Tyr Val Asp Ser Pro Gly Gly Thr Thr Leu His Ile Asp Asp Val Arg  
           1265                           1270                           1275                           1280  
 30           gta acc aaa caa taa   3855  
           Val Thr Lys Gln

35

**Claims**


- 40   1. A branched cyclotetrasaccharide which is a glycosyl derivative of cyclotetrasaccharide represented by cyclo(→  
           6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→6)-α-D-glucopyranosyl-(1→3)-α-D-glucopyranosyl-(1→),  
           and which has a structure represented by Formula 1;

45

50

55

Formula 1:



wherein in Formula 1,  $R_1$  to  $R_{12}$  each independently represents an optionally substituted glycosyl group or hydrogen atom, with the proviso that when all of  $R_1$  to  $R_{12}$  are not hydrogen atom and either  $R_4$  or  $R_{10}$  is an optionally substituted glycosyl group,  $R_4$  or  $R_{10}$  as the glycosyl group is a member selected from the group consisting of glycosyl groups other than D-glucopyranosyl group.

2. The branched cyclotetrasaccharide of claim 1, wherein one or more glycosyl groups positioning at one or more positions of  $R_1$  to  $R_{12}$  in Formula 1 each independently represent any one of the glycosyl groups selected from those represented by the following groups of (1) to (5):

(1) optionally substituted  $\{\alpha\text{-D-glucopyranosyl-(1}\rightarrow\text{4)-}\}_n \alpha\text{-D-glucopyranosyl}$  groups, with the proviso that each "n" in the above groups independently means an integer of 0 or more when at least two of  $R_1$  to  $R_{12}$  are the above groups;

(2) optionally substituted  $\alpha\text{-D-glucopyranosyl-(1}\rightarrow\text{6)-}\{\alpha\text{-D-glucopyranosyl-(1}\rightarrow\text{3)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow\text{6)-}\}_n \alpha\text{-D-glucopyranosyl}$  groups, with the proviso that each "n" in the above groups independently means an integer of 0 or more when at least two of  $R_1$  to  $R_{12}$  are the above groups;

(3) optionally substituted  $\{\beta\text{-D-galactopyranosyl-(1}\rightarrow\text{6)-}\}_n \beta\text{-D-galactopyranosyl}$  groups, with the proviso that each "n" in the above groups independently means an integer of 0 or more when at least two of  $R_1$  to  $R_{12}$  are the above groups;

(4) optionally substituted  $\alpha\text{-D-galactopyranosyl}$  groups; and

(5) optionally substituted  $\beta\text{-D-chitosaminy}$  groups.

3. The branched cyclotetrasaccharide of claim 1 or 2, wherein  $R_1$  and/or  $R_7$  in Formula 1 are independently optionally substituted  $\{\alpha\text{-D-glucopyranosyl-(1}\rightarrow\text{4)-}\}_n \alpha\text{-D-glucopyranosyl}$  groups, with the proviso that each "n" in the above groups independently means an integer of 0 or more when both  $R_1$  and  $R_7$  are the above groups.

4. The branched cyclotetrasaccharide of claim 3, which is the one represented by Chemical Formula 1 or 2;

Chemical Formula 1:

$$\begin{array}{c} \text{cyclo}\{\rightarrow 6\}-\alpha\text{-D-Glcp}-(1\rightarrow 3)-\alpha\text{-D-Glcp}-(1\rightarrow 6)-\alpha\text{-D-Glcp}-(1\rightarrow 3)-\alpha\text{-D-Glcp}-(1\rightarrow) \\ | \\ 4 \\ | \\ 1 \\ | \\ \alpha\text{-D-Glcp} \end{array}$$

Chemical Formula 2:

$$\begin{array}{c} \text{cyclo}\{-6\}-\alpha\text{-D-Glcp-}(1\rightarrow3)-\alpha\text{-D-Glcp-}(1\rightarrow6)-\alpha\text{-D-Glcp-}(1\rightarrow3)-\alpha\text{-D-Glcp-}(1\rightarrow) \\ \quad \quad \quad \uparrow \quad \quad \quad \uparrow \\ \quad \quad \quad 1 \quad \quad \quad 1 \\ \quad \quad \quad \alpha\text{-D-Glcp} \quad \quad \quad \alpha\text{-D-Glcp} \end{array}$$

5. The branched cyclotetrasaccharide of claim 1, 2 or 3, wherein R<sub>2</sub> and/or R<sub>8</sub> in Formula 1 are optionally substituted α-D-glucopyranosyl-(1 → 6)-{α-D-glucopyranosyl-(1 → 3)-α-D-glucopyranosyl-(1 → 6)-}<sub>n</sub> α-D-glucopyranosyl groups, with the proviso that each "n" in the above groups independently means an integer of 0 or more when both R<sub>2</sub> and R<sub>8</sub> are the above groups.
6. The branched cyclotetrasaccharide of claim 5, which is the one represented by Chemical Formula 3, 4, or 5;


Chemical Formula 3:

[illegible]

Chemical Formula 4:

[illegible]


## Chemical Formula 5:



7. The branched cyclotetrasaccharide of any one of claims 1 to 3, wherein  $R_2$  and/or  $R_8$  in Formula 1 are optionally substituted  $\{\beta\text{-D-galactopyranosyl}-(1\rightarrow 6)-\}_n\beta\text{-D-galactopyranosyl}$  groups, with the proviso that each "n" in the above groups independently means an integer of 0 or more when both  $R_2$  and  $R_8$  are the above groups.

8. The branched cyclotetrasaccharide of claim 7, which is the one represented by Chemical Formula 6;


## Chemical Formula 6:




9. The branched cyclotetrasaccharide of claim 1, 2 or 3, wherein  $R_4$  and/or  $R_{10}$  in Formula 1 are optionally substituted  $\{\beta\text{-D-galactopyranosyl}-(1\rightarrow 6)-\}_n\beta\text{-D-galactopyranosyl}$  groups, with the proviso that each "n" in the above groups independently means an integer of 0 or more when both  $R_4$  and  $R_{10}$  are the groups.

10. The branched cyclotetrasaccharide of claim 7, which is the one represented by Chemical Formula 7 or 8;

## Chemical Formula 7:



## Chemical Formula 8:







crystalline powder.

22. A process for producing a branched cyclotetrasaccharide which uses the action of an enzyme capable of transferring a glycosyl group from a monosaccharide, oligosaccharide, or polysaccharide to cyclotetrasaccharide represented by  $\text{cyclo}\{\rightarrow 6\}\text{-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 3\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 6\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 3\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow\}$ , and which is **characterized in that** it comprises the following two steps of;

(1) forming the branched cyclotetrasaccharide of any one of claims 1 to 14 by allowing the enzyme to act on a mixture of the cyclotetrasaccharide along with the monosaccharide, the oligosaccharide, or the polysaccharide, and

(2) collecting the formed branched cyclotetrasaccharide in the step (1).

23. The process of claim 22, which further contains the following step for producing the cyclotetrasaccharide prior to the step (1);

forming the cyclotetrasaccharide by allowing an  $\alpha$  - isomaltosylglucosaccharide-forming enzyme, having the following enzymatic activity (A) and an  $\alpha$ -isomaltosyl-transferring enzyme having the following enzymatic activity (B), to act on a saccharide having both a glucose polymerization degree of at least two and the  $\alpha$ -1, 4 glucosyl bond as a linkage at the non-reducing end, and collecting the formed cyclotetrasaccharide;

Enzymatic activity (A): Acting on a saccharide, having both a glucose polymerization degree of "n" ("n" is an integer of two or more) and the  $\alpha$ -1, 4 glucosyl bond as a linkage at the non-reducing end, and forming a saccharide having a glucose polymerization degree of "n+1" and having both the  $\alpha$ -1, 6 glucosyl bond as a linkage at the non-reducing end and the  $\alpha$ -1, 4 glucosyl bond as a linkage other than the non-reducing end, without substantially increasing the reducing power; and

Enzymatic activity (B): Acting on a saccharide, having a glucose polymerization degree of at least three and having both the  $\alpha$ -1, 6 glucosyl bond as a linkage at the non-reducing end and the  $\alpha$ -1, 4 glucosyl bond as a linkage other than the non-reducing end, and forming cyclotetrasaccharide represented by  $\text{cyclo}\{\rightarrow 6\}\text{-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 3\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 6\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 3\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow\}$ .

24. The process for producing a branched cyclotetrasaccharide of claim 22 or 23, which uses one or more enzymes selected from the group consisting of cyclomaltodextrin glucanotransferase,  $\beta$  -galactosidase,  $\alpha$  -galactosidase, lysozyme, an  $\alpha$  -isomaltosylglucosaccharide-forming enzyme having the following enzymatic activity (A), and an  $\alpha$ -isomaltosyl-transferring enzyme having the following enzymatic activity (B), which are enzymes capable of transferring a glycosyl group from a monosaccharide, oligosaccharide, or polysaccharide to cyclotetrasaccharide;

Enzymatic activity (A): Acting on a saccharide, having the 1,4-glucosyl bond and a glucose polymerization degree of "n" ("n" is an integer of two or more, and forming a saccharide, having a glucose polymerization degree of "n+1" and having both the  $\alpha$ -1, 6 glucosyl bond as a linkage at the non-reducing end and the  $\alpha$ -1, 4 glucosyl bond as a linkage other than the non-reducing end, without substantially increasing the reducing power; and

Enzymatic activity (B): Acting on a saccharide, having a glucose polymerization degree of at least three and having both the  $\alpha$ -1, 6 glucosyl bond as a linkage at the non-reducing end and the  $\alpha$ -1, 4 glucosyl bond as a linkage other than the non-reducing end, and forming a cyclotetrasaccharide represented by  $\text{cyclo}\{\rightarrow 6\}\text{-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 3\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 6\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 3\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow\}$ .

25. The process of claim 22, 23, or 24, which uses, as the monosaccharide, oligosaccharide or polysaccharide, one or more saccharides selected from the group consisting of glucose-1-phosphate, maltooligosaccharide, circular dextrin, panose, isomaltosylglucosaccharide, lactose, melibiose, N-acetyl chitooligosaccharide, dextrin, glycogen, liquefied starch, and chitin as a monosaccharide, oligosaccharide, and polysaccharide.

26. The process of any one of claims 22 to 25, wherein the formed branched cyclotetrasaccharide is collected by a step comprising one or more purification methods selected from the group consisting of decoloration, desalting, column chromatography, and crystallization.

27. A method for transferring a glycosyl group using an enzyme capable of transferring a glycosyl group from a monosaccharide, oligosaccharide, or polysaccharide to a cyclotetrasaccharide represented by  $\text{cyclo}\{\rightarrow 6\}\text{-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 3\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 6\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow 3\text{)-}\alpha\text{-D-glucopyranosyl-(1}\rightarrow\}$ ; said method comprising a step of allowing the enzyme to act on a mixture of cyclotetrasaccharide and the monosaccharide, oligosaccharide, or polysaccharide to form the branched cyclotetrasaccharide of any one of claims 1 to 14.

28. A composition comprising the branched cyclotetrasaccharide of any one of claims 1 to 14.

29. The composition of claim 28, which is in the form of a food, cosmetic, or pharmaceutical.

5

10

15

20

25

30

35

40

45

50

55

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6





FIG. 7





(a) FIG. 8a




FIG. 8b

(b)




FIG. 9




FIG. 10




FIG. 11




FIG. 12






FIG. 13FIG. 14


FIG. 15


FIG. 16

FIG. 17






FIG. 18





FIG. 19


FIG. 20


FIG. 21


FIG. 22

FIG. 23





FIG. 24



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP02/02213

## A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl<sup>7</sup> C07H/06, C08B37/00, C12P19/00, A23L1/30<A61K47/26, 7/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl<sup>7</sup> C07H/06, C08B37/00, C12P19/00, A23L1/30<A61K47/26, 7/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAPLUS (STN), RESISTRY (STN), MEDLINE (STN), EMBASE (STN)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	WO 02/10361 A1 (Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyuujo), 07 February, 2002 (07.02.02), (Family: none) & Database CAPLUS on STN, American Chemical Society (ACS), (Columbus, OH, USA), DN.136:163295	1-29
P, A	WO 01/90338 A1 (Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyuujo), 29 November, 2001 (29.11.01), (Family: none) & Database CAPLUS on STN, American Chemical Society (ACS), (Columbus, OH, USA), DN.136:2254	1-29

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search  
15 May, 2002 (15.05.02)Date of mailing of the international search report  
28 May, 2002 (28.05.02)Name and mailing address of the ISA/  
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

Form PCT/ISA/210 (second sheet) (July 1998)



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP02/02213

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5786196 A (The United States of America as Represented by The Secretary of Agriculture), 28 July, 1998 (28.07.98), & US 5889179 A & US 5888776 A	1-29

Form PCT/ISA/210 (continuation of second sheet) (July 1998)